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Abstract
Galectins are a group of β-galactoside-binding proteins involved in different cellular
processes including stress responses and differentiation. The role and expression of
galectins under oxidative stress and during neutrophilic differentiation was examined in
HL-60 cells. Galectin gene (LGALS), and galectin protein expression were determined
using RT-qPCR and immunoblotting, respectively. Neutrophilic differentiation was
measured via a spectrofluorometric assay. DNA methylation and JNK signaling were
investigated as galectin regulatory mechanisms. Menadione-induced oxidative stress,
DMSO-induced differentiation, DNA hypomethylation and JNK signaling all promoted
similar galectin expression profiles. Antioxidant N-acetylcysteine attenuated the
menadione-induced galectin expression but only partially attenuated DMSO-induced
galectin expression. Galectin inhibitory sugars decreased cell proliferation and inhibited
differentiation. Finally, correlative analysis suggests galectins are biomarkers of oxidative
stress and cellular differentiation. My findings indicate that galectins represent novel
therapeutic targets in the context of acute myeloid leukemia and their expression profiles
can be considered biomarkers of oxidative cell stress and differentiation.
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Chapter 1

1

Introduction

1.1 Galectins – an overview
Galectins are a family of glycan-binding proteins with binding specificity toward βgalactosides (Barondes et al., 1994). Originally, discovered in 1975 by Teichberg et al. the
first vertebrate galectin from Electrophorus electricus (eel) was originally named
“electrolectin”, and was found to be inhibited by β-ᴅ-galactosyl residues while having
lectin like activity within mammalian cell culture (Teichberg et al., 1975). Shortly
thereafter other research groups started purifying related lectins from other vertebrate
tissues. Galectin-1 was purified in 1976 from calf heart and lung (de Waard et al., 1976),
and the first avian galectin from chicken muscles (Nowak et al., 1976). Some years later
galectin-3 was identified in fibroblasts (Roff and Wang, 1983), and then purified a year
later from mouse lung (Crittenden et al., 1984). Galectins are relatively small in size and
have specific binding toward N-acetyllactosamine-enriched glycoconjugates. They are part
of a larger family of proteins known as lectins that are found more predominately in plants
and exhibit high specificity toward many different sugar moieties (Varki et al., 2009). Since
their original discovery galectins have undergone various name changes including:
galaptin, S-Lac and S-type lectins before finally being designated as “galectin” in 1994 to
avoid name discrepancies (Allen et al., 1990; Barondes et al., 1994; Thiemann and Baum,
2016). Today, 16 galectin genes have been identified in mammals with 12 galectins being
characterized and sequenced in humans (Thiemann and Baum, 2016; Timoshenko, 2015)
however, these proteins have been identified across all eukaryotic taxa. Others, for
example, galectin-5 and -6 are found in rodents, while galectin-11 has been identified in
sheep, but is not found in humans (Varki et al., 2009). Galectin activity has been well
reported across many tissues and their differential regulation is important for maintaining
cellular functions (Laderach et al., 2013). Since their original discovery, galectins have
been identified in both vertebrates and invertebrates including: mammals, amphibians, fish,
birds, reptiles, nematodes, sponges and even fungi (Gupta, 2012).
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Galectins may be secreted into the extracellular matrix where they will bind their
appropriate glycoreceptor at the cell surface; initiating a signal transduction pathway,
which drives gene expression of factors important for various biological functions.
Specifically, galectins serve as mediators of several fundamental biological processes
including: cell growth (Manzi et al., 2016), apoptosis (Stillman et al., 2006), immune
function (Chung et al., 2013), differentiation (Abedin et al., 2003), migration and adhesion
(Perillo et al., 1998). Although all galectins display affinity toward lactose – Nacetyllactosamine and poly-N-acetyllactosamine residues are located on different
glycoconjugates and modification of these sugar moieties can define galectin specific
binding/functionality (Ahmad et al., 2004). Even though galactose is the basic recognition
element for many galectins; actual glycans present on different proteins/lipids at the cell
surface are more complicated in vivo. Galectins typically exist as dimers (also multimers)
allowing a single galectin to bind multiple sites. Lectin-carbohydrate interactions are
relatively weak; therefore, structural orientation of the peptide sequence of the galectin can
allow for multiple galectin binding domains to bind their respective ligand at the same time,
creating a stronger interaction and lowering the dissociation constant. For example,
generally, galectins bind glycoreceptors containing N-acetyllactosamine residues with a
dissociation constant (Kd) of 90 – 100 µM but galectins can also bind glycoreceptors
containing polylactosamine sequences with stronger affinity: Kd value of 1 µM
(Rabinovich et al., 2002). In a biological context, galectins do not bind the simple
disaccharides alone but rather lactosamine sequences that are present on complex Nglycans and O-glycans on numerous branches leading to high-avidity binding since the
affinity of each galectin binding site for its respective ligand is additive in a multimeric
complex (Thiemann and Baum, 2016). Therefore, it is important to understand the
structural differences of galectins to better define their roles in different tissues and explain
why certain galectins are only expressed within specific tissues while others are not.

1.2 Structural features and classification
Galectins are grouped according to their structural domain composition (Hirabayashi and
Kasai, 1993). Specifically, all galectins are characterized, identified and often classified
according to their respective carbohydrate recognition domain(s) (CRD). The CRD
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consists of about 135 amino acids, composing two protein β-sheets, which are formed by
five and six β-strands each folded antiparallel to each other forming a pocket for the
respective glycan to bind (Cooper, 2002; Thiemann and Baum, 2016). All galectins contain
either one or multiple CRDs, distinguishing homo-dimeric from hetero-dimeric galectins.
Galectins were once originally referred to as S-type lectins; this was to denote that many
galectins contained free cysteine residues (Varki et al., 2009). In fact, it has been stated
that certain galectins required the inclusion of β-mercaptoethanol in buffers to maintain
their activity, perhaps because of the disulfide linkage of cysteine residues – important for
proteins structure (Varki et al., 2009). More recent studies have shown that, mouse
galectin-2 for example, only require a certain cysteine (Cys75) residue present in the amino
acid motif of the CRD for this domain to exhibit lectin-binding capabilities while
mutagenesis of other conserved free cysteine residues had no effect (Tamura et al., 2016).
Galectin-1 for example, contains six cysteine residues (Cys2-Cys16, Cys42-Cys60, Cys88Cys130), which are required to be in a reduced state to allow for proper carbohydrate
binding activity and biological function (Kadoya and Horie, 2005; Klyosov, 2008).
However, other studies have shown that site-directed mutagenesis of these cysteine
residues into serine residues did not inhibit sugar binding (Liao et al., 1994) but that
mutagenesis of other conserved hydrophilic residues abolished carbohydrate binding
activity (Hirabayashi and Kasai, 1991). Interestingly, the amino acid sequences of the CRD
are highly homologous across and within species (90% of the 134 amino acids are identical
between humans and mice) (Kadoya and Horie, 2005). The structural features and
organization of the CRD categorize galectins into the following 3 sub-families: proto-type,
tandem-repeat and chimeric galectins.
Despite the CRD playing a dominant role in galectin function; other non-lectin domains
also play functional roles. In fact, non-lectin domains of galectins are often crucial for
specific protein-protein interactions – despite being less frequent than CRD-dependent
interactions. Park et al. (2001) demonstrate that galectin-1 and -3 are factors required for
pre-mRNA splicing within HeLa cells through a non CRD-dependent interaction (Park et
al., 2001). Additionally, intracellular galectin-1 has been reported to interact with H-Ras,
a gene frequently mutated in tumours to promote malignant differentiation, in multiple cell
lines including HeLa, HEK293, Rat1 and Molt4 in a CRD-independent fashion (Camby et
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al., 2006; Yu et al., 2015). Interestingly, Liu et al. (1996) used murine monoclonal
antibodies to bind epitopes along the amino-terminal region of galectin-3, which inhibited
galectin-mediated superoxide production (Liu et al., 1996). In fact, most galectins have
features typical of cytoplasmic proteins including an acetylated N-terminus, free thiol
groups and absence of glycosylation, which inherently affects their localization and
functional capacity.
Galectin localization is important for determining their function. These proteins can work
both intracellularly by interacting with various intracellular ligands or extracellularly by
mediating cell-cell, cell-matrix interactions and by binding cell surface glycans to activate
a signal transduction pathway (Gupta, 2012; Varki et al., 2009). Galectin-1 shows multiple
functions depending on its subcellular localization. Intracellularly, galectin-1 can arrest cell
growth while extracellular galectin-1 can induce proliferation or apoptosis (Stillman et al.,
2005). Contrasting roles in galectin-1 localization function are likely due to CRDdependent interactions happening exclusively in the extracellular matrix. Interestingly,
however, galectins lack any signal sequence for classical secretion into the extracellular
space despite the regulation of galectin secretion being markedly changed during different
cellular processes (Hirabayashi and Kasai, 1993; Sato and Hughes, 1994). Additionally,
structural characteristics of galectins including an acetylated N-terminus, absence of both
disulfide bonds and glycan chains indicate that these proteins would normally reside within
the cytoplasm despite being biologically active in the extracellular space and on the cell
surface. It is surprising that galectins are secreted at all considering the oxidizing
environment of the extracellular space (which would affect galectin folding). Therefore,
the biological function of galectins in the oxidative extracellular space may be dependent
on their immediate binding to glycoreceptors, which would prevent oxidation of free
cysteine residues (Vasta, 2009). It has been proposed that galectins may exit cells according
to the structure of the protein, the cell type and its polarity (Hughes 1999). Interestingly,
different cell types secrete different levels of total produced galectin. CHO-K1 cells have
been reported to secrete all expressed galectin-3 (Sato et al., 1993) while BHK-21 cells
secrete only 12% (Lindstedt et al., 1993). Identification of secreted galectins and their
localization within different tissues is clinically important especially when designing drugs
that bind galectins as therapeutic targets particularly those that are overexpressed in
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different cancers. Despite the accumulation of data on individual galectins, there is still no
galectin “signature/profile” that identifies their function across cell types (Laderach et al.,
2013). This is, in part, due to galectins displaying multifaceted biological functions. For
example, galectin-3 has been reported to display both anti-apoptotic and pro-apoptotic
effects (Fukumori et al., 2003; Nakahara et al., 2005). Often many differences in galectin
expression can be seen across various cancer lines (Satelli et al., 2008), and even altered
galectin transcript levels, which are dependent on specific cellular differentiation events
(Abedin et al., 2003).
Prototypical galectins
The galectins in this family are galectin-1, -2, -5, -7, -10, -11, -13, -14, -15 and -16.
Prototypical galectins are generally smaller (14-16 kDa) than others and have a single
galactoside binding domain with a short peptide region followed by an N-terminal
sequence. These proteins can exist either as a galectin monomer or more typically as a
homodimer. There are 8 conserved amino acids in the CRD that allow for proper binding
of prototypical galectins (Hirabayashi and Kasai, 1991; Lobsanov et al., 1993). Monomeric
galectins consist of galectin-5, -10 and -14 while galectins-1, -2, -7, -11, -13, -15 and -16
exist as non-covalent homodimers.
Tandem-repeat galectins
Galectin-4, -6, -8, -9 and -12 fall under this subfamily and are generally larger (between
35-39 kDa) than other galectins. These galectins contain two non-identical CRDs: one
being located at the N-terminus with the other at the C-terminus, linked together by a short
linker peptide region that is roughly 25 – 35 amino acids in size – highly rich in proline
and glycine residues. There is evidence that this linker region increases susceptibility of
these proteins to proteolysis and that truncated versions increase resistance toward
degradation (Nishi et al., 2005). As a result, these galectins are typically less stable than
the others.
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Chimeric galectins
Currently, galectin-3 is the only galectin classified as a chimeric type and it is 26 kDa in
size. This monomeric galectin contains two functional domains: the N-terminal regulatory
domain and the C-terminal CRD. The N-terminal regulatory domain contains many
repeated collagen-like sequences (7-14 regions with 8-11 amino acids in each) (Rapoport
et al., 2008; Weis and Drickamer, 1994), and shares high homology with the heterogeneous
nuclear ribonucleoprotein complex (Jia and Wang, 1988). The regulatory domain of
galectin-3 is also phosphorylated on at least two different residues and is susceptible to
cleavage by enzymes that impact its ability for both lectin binding and self-oligomerization
(Balan et al., 2012; Rapoport et al., 2008). Oligomerization is a unique trait of galectin-3,
which allows this protein to form galectin-glycan structures between and across cell
surfaces.
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Figure 1. Classification of galectins based on their molecular structure. Galectins are
classified based on their carbohydrate recognition domains (black and grey), nonlectin linker domain (blue and light blue) and N-terminal end domains (brown).
Illustration above shows the basic molecular characteristics of human galectins (adapted
from Timoshenko et al. [2016]). Prototype galectins may form homodimers (not shown).
Tandem-repeat galectins contain two non-identical CRDs joined together by a short linker
peptide region. Chimeric galectin-3 is monomeric, however, may oligomerize using its Nterminal end domain (brown circle) to form pentamers.
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1.3 Cellular functions of galectins
Numerous studies have shown that galectins play prominent roles in cell signaling,
crosslinking and interactions with a variety of ECM molecules. This is achieved by
galectins through their ability to interact with glycolipids (Ahmed et al., 2002),
glycoprotein receptors (Stillman et al., 2006), integrins (Friedrichs et al., 2008) and other
ligands to mediate cellular functions (Boscher et al., 2011). Further, galectins often regulate
other molecular targets to facilitate these biological functions. For example, exposure
treatment of galectin-1, -2, -3, -4 and -7 promotes adhesion of human breast cancer cells
accompanied by increased production of the lymphangiogenic factor: vascular endothelial
growth factor-C (VEGF-C) (Timoshenko et al., 2010). Further, galectins induce a variety
of functional cellular responses such as aggregation of blood and immune cells, activation
of neutrophils (production of ROS and degranulation), and an increase in cytoplasmic Ca2+
availability (Timoshenko et al., 1995, 1997, 2003). Each galectin has slightly different
affinity toward galactose, dependent on glycan structural organization on the cell surface
with other complex oligosaccharides. Moreover, structural differences between galectins
allow each galectin to maintain a certain role within different tissues despite significant
homology.
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Figure 2. Interactions between cell surface glycoconjugates (black cylinders represent
transmembrane receptors, orange circles and squares represent galactose-containing
oligosaccharides) with various galectin family members (green proto, blue chimeric,
yellow tandem-repeat) which facilitates cellular functions.
The illustration above demonstrates the facilitation of galectin binding which can mediate
signal transduction and cell adhesion events, among others (adapted from Liu and
Rabinovich [2005]).
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1.3.1

Galectin-1

Generally, galectin-1 is differentially expressed by both tumourigenic and normal tissues,
mediating of a wide variety of biological functions that are dependent on proteincarbohydrate and protein-protein interactions (Camby et al., 2006). Galectin-1 is typically
associated with initiating and augmenting inflammatory responses including apoptosis,
adhesion and migration. This galectin is capable of inducing cell death of both resting
(Perillo et al., 1995), and activated (Matarrese et al., 2005) T-cells. Similarly, upregulation
of galectin-1 expression promotes apoptosis in rat macrophages and activated T-cells,
suppress in vitro T-cell activation and inhibits cellular proliferation (Blaser et al., 1998;
Rabinovich et al., 1998). Cells overexpressing galectin-1 are able to increase cell migration
by binding, in a CRD-dependent manner, to fibronectin, laminin and collagen (Horiguchi
et al., 2003) through cross-linking glycoproteins exposed on the cell surface. Interestingly,
galectin-1 can differentially impact the effect of cell proliferation depending on cell type.
For example, galectin-1 has been shown to inhibit proliferation in lymphocytes,
neuroblastoma and prostate cancer while increasing cell proliferation in cervical, ovarian
and pancreatic tumour cells (Vladoiu et al., 2014). More interestingly, galectin-1 has been
shown to elicit contrasting effects on the same cell type. Yamaoka et al. (2000)
demonstrated that inhibition of the galectin-1 gene (LGALS1) decreases rat brain tumour
cell proliferation while Kopitz et al. (2001) showed that administration of recombinant
galectin-1 inhibited brain tumour growth (Kopitz et al., 2001; Yamaoka et al., 2000).
Most evidence, however, suggests galectin-1 as a master regulator of various immune
responses including T-cell survival and immune disorders, inflammation and allergies
(Gupta, 2012) achieved by binding of various glycoconjugate receptors (CD45, CD32 and
CD7) (Pace et al., 1999). Most interestingly, it has been shown that secreted galectin-1 is
able to promote tumour cell evasion of the immune response; likely mediated by binding
CD4 and CD8 receptors of immune T-cells to promote apoptosis (Rubinstein et al., 2004),
an effect that can be attenuated by the addition of lactose. Typically this galectin works in
an anti-inflammatory manner by suppressing the secretion of the pro-inflammatory
cytokine interleukin-2 (IL-2) (Rabinovich et al., 1999), and promoting the release of antiinflammatory cytokine interleukin-10 (IL-10) (van der Leij et al., 2004). Kiss et al. (2007)
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provide evidence of reduced swelling through edema assay testing providing more
evidence of an anti-inflammatory role for this galectin (Kiss et al., 2007). Today, many CD
receptors have been recognized as galectin-1 binding partners (Elola et al., 2005), however,
it has been shown that different galectins have a specific preference for separate
glycoprotein CD receptors despite high CRD homology (Stillman et al., 2006).

1.3.2

Galectin-3

There is a considerable amount of literature on galectin-3 highlighting its biological
activity, which is strongly influenced by its localization, cell type, neoplastic processes,
cellular proliferation status and others (Dumic et al., 2006). The localization of galectin-3
can strongly affect its biological activity. Generally, intracellular galectin-3 acts as an antiapoptotic factor while extracellular galectin-3 is pro-apoptotic (Dumic et al., 2006).
Galectin-3 has been shown to work intracellularly with multiple different ligands in the
cytoplasm including Bcl-2 (Akahani et al., 1997; Yang et al., 1996), APO-1/Fas (Fukumori
et al., 2004), Nucling (Liu et al., 2004), and AIPI (Liu et al., 2002) to mediate apoptotic
events (either pro- or anti-apoptotic).
Galectin-3 is able to work in the nucleus to mediate gene transcription that affects cell
proliferation (Paron et al., 2003), and cell cycle regulation (Kim et al., 1999). Similar to
the only documented function of nuclear galectin-1; galectin-3 is also capable of binding
Gemin-4 subsequently affecting post-transcriptional regulation of mRNA processing
(Paushkin et al., 2002).
Extracellular galectin-3 is able to mediate cell-ECM interaction through binding to laminin,
fibronectin, elastin, collagen IV and mediate cell-cell interactions through preferential
binding to the ligand N-acetyllactosamine located on CD receptors and glycoreceptors
(Dumic et al., 2006). In this way, galectin-3 regulates cell adhesion and migration primarily
through interaction with integrins in a CRD-dependent manner (Ochieng et al., 1998).
Similar to galectin-1, galectin-3 is also predominately involved in immune function.
Galectin-3 can bind CD receptors to suppress apoptosis or increase proliferation (Akahani
et al., 1997; Yang et al., 1996). It has been proposed that the role of galectin-3 is to
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oligomerize with itself and then bridge monocyte activated macrophages to apoptotic
neutrophils in order to increase their uptake (Karlsson et al., 2009) suggesting that the
structural characteristics (divalent vs multivalent), and glycan specificity (receptor
selectivity) provide contrasting roles for similar galectins.
The maintenance of endogenous galectins is crucial in their ability to carry out biological
roles. For example, phosphorylation of the regulatory domain of galectin-3 is critical for
protecting it from subsequent cleavage by the prostate specific antigen (Balan et al., 2012).
This provides evidence of the phosphorylated/non-phosphorylated galectin-3 ratio as a
prognostic marker of prostate cancer considering intact galectin-3 increases levels of
angiogenesis and metastasis. Galectin-3 may also be used as a marker of cellular stress
responses considering many tumourigenic processes are involved with different types of
cell stress.
Additionally, galectin-3 expression is vastly upregulated near sites of inflammation.
Galectin-3 is typically described as a pro-inflammatory galectin, in contrast to galectin-1.
Galectin-3 can potentiate inflammatory responses by increasing superoxide anion
production, increase adhesion of neutrophils to components of the ECM and work in a
similar fashion to that of cytokines to affect both innate and adaptive immunity. Another
interesting quality of this galectin during immune response is that it is able to recognize
glycoreceptors present on foreign pathogens (Mandrell et al., 1994). Although the specific
function for galectin-3 binding foreign pathogens is not well understood, galectin-3
knockout murine models display a reduced ability to clear infection (Beatty et al., 2002),
and develop fewer white blood cells than wild type mice (Zuberi et al., 2004).

1.3.3

Galectins-8, -9, -10 and -12

Galectin-8 is a tandem-repeat galectin that effects a wide variety of functions including cell
adhesion, cell proliferation, apoptosis and others (Tribulatti et al., 2007; Zick et al., 2004).
Interestingly, this galectin has also elicited opposing roles dependent on cell type. For
example, galectin-8 has been shown to induce apoptosis in thymocytes (Tribulatti et al.,
2007) while preventing apoptosis in brain cancer (Metz et al., 2016). This galectin is well
characterized in cancer and its expression levels correlate with the degree of malignancy
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and differentiation of different tumours (Bidon-Wagner and Le Pennec, 2004). In fact, a
galectin finger-printing study revealed that galectin-8 was detected in all but two of 61
different human tumour cell lines and was more highly expressed than galectins-1, -2, -3,
-4, -7 and -9 (Lahm et al., 2001).
Galectin-9 is also a tandem-repeat galectin classically known to be a regulator of both
adaptive and innate immunity and functions by inducing secretion of a variety of cytokines
from different blood cells (Kojima et al., 2014; Matsuura et al., 2009). Recently, increased
galectin-9 expression has been suggested as a marker of distinct cancer types where other
galectins are notably downregulated (Muniz et al., 2015).
Galectin-10, also known as Charcot-Leyden crystal protein, is a major component of
eosinophils (Dyer and Rosenberg, 1996). Originally found to have affinity for galactosyl
residues; this galectin shows higher affinity toward mannosyl residues (Dyer and
Rosenberg, 1996; Swaminathan et al., 1999). This galectin is believed to be a mediator and
potential biomarker of eosinophilic airway inflammation based on its accumulation within
sputum (Chua et al., 2012), and in peripheral blood from patients suffering from bronchial
inflammation (Devouassoux et al., 2008).
Galectin-12 is a tandem-repeat galectin, typically expressed in leukocytes and adipose
tissue that was cloned originally by Yang et al. (2001), and was found to impact the cell
cycle of cancer cells. Although galectin-12 expression across most tissues is relatively
weak, it is reported to have relatively high expression in acute promyelocytic leukemia
(Timoshenko et al., 2016; Xue et al., 2016), and is involved with regulating adipocyte
differentiation (Yang et al., 2004).

1.4 Oxidative stress
Oxidative stress can be defined as a disturbance in the balance between reactive oxygen
species (ROS) production and antioxidant detoxification, leading to tissue damage
(Betteridge, 2000). Maintaining a proper physiological redox status in a cell is crucial for
cell survival and homeostasis. ROS may be produced by dedicated enzyme complexes i.e.
NOX family of NADPH oxidases, or as by-products of oxidation-reduction reactions
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(Janssen-Heininger et al., 2008; Murphy, 2009; Tochhawng et al., 2013). Induced oxidative
stress can be achieved in vitro through exogenous administration of H2O2 or specific
chemical inducers. For instance, 2-methyl-1,4-naphthoquinone (menadione) is a redox
cycling compound that undergoes reduction via intracellular enzymes reducing molecular
oxygen to a free radical superoxide anion (Criddle et al., 2006). Menadione has been shown
to induce significant levels of H2O2 (Timoshenko et al., 1996). Additionally, the hypoxia
mimetic agent, cobalt chloride (CoCl2) has been shown to induce ROS via a mechanism
that is non-mitochondrial (Chandel et al., 1998; Kotake-Nara and Saida, 2007). Free
radicals consist of one or more unpaired electrons making them extremely reactive with
various cellular components including lipids, proteins, nucleic acids and carbohydrates in
comparison to non-radicals (Halliwell, 1994; Tsukahara, 2007). Damage often occurs
when the antioxidant defense system is inefficient or when ROS levels rise excessively,
leading to free radical induced apoptosis. Often anti-apoptotic genes in certain cells appear
to encode free radical scavengers i.e. glutathione or antioxidant enzymes i.e. glutathione
peroxidase (GPX) or heme oxygenase 1 (ho-1) as a means to counter the stress (Dobashi
et al., 2001; Sarafian and Bredesen, 1994). ho-1 catabolizes cellular heme into biliverdin
carbon monoxide and free iron. It is strongly upregulated during oxidative stress and is
documented as one of the sensitive and reliable markers of oxidative stress (Choi and Alam,
1996; Poss and Tonegawa, 1997). Although an abundance of ROS may lead to oxidative
damage; appropriate levels of ROS must be present to maintain physiological conditions.
In fact, rapid ROS production known as oxidative “burst” is an important function of
immune cells in which case large amounts of ROS are produced by oxidation of NADPH
in order to combat foreign pathogens. Neutrophils and other phagocytes are often
responsible and present at sites of inflammation in order to maintain healthy conditions. At
the site of infection, neutrophils are the earliest of granulocytes recruited and release
antimicrobial compounds from their granules in addition to the production of ROS in order
to kill invading pathogens (van Gisbergen et al., 2005).
Oxidative stress is clinically relevant and has been implicated in the development of
various diseases/disorders, a short list of which include: cancer (Reuter et al., 2010),
Alzheimer’s (Christen, 2000), Parkinson’s (Blesa et al., 2015), Huntington’s (Gil-Mohapel
et al., 2014) cardiovascular diseases (Dhalla et al., 2000), autism (Chauhan and Chauhan,
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2006), and depression (Michel et al., 2012). In the event of oxidative stress, the cell has
numerous stress response mechanisms that have evolved in order to deal with increased
ROS. Often, oxidative stress activates numerous signaling pathways that are involved with
gene expression changes that ultimately govern the cells fate of either survival or death.
ROS are known to activate pro-inflammatory signaling pathways causing the activation of
mitogen-activated protein kinase (MAPK) dependent transcription factors including, NFĸB, which following activation is translocated to the nucleus to modulate gene expression
changes of several cytokines to induce apoptosis, inflammation and fibrosis (Bierhaus et
al., 1997; Pugliese et al., 2015), and is well characterized within immune cells (Dumic et
al., 2006). In particular, activation of MAPKs include a large number of serine/threonine
kinases falling under the extracellular signal-regulated kinases (ERK), c-Jun N-terminal
kinases (JNK), and p38 subfamilies, which are responsible for activation of various genes
relevant for antioxidant defenses (Martindale and Holbrook, 2002). Further, oxidative
stress has also been found to regulate transcription factors directly including: NF-ĸB
(Gloire et al., 2006), p53 (Liu et al., 2008a), Nrf2 (Ma, 2013), HSF1 (Ahn and Thiele,
2003), and others. In certain diseases, these factors promote cellular proliferation,
apoptosis, transformation, angiogenesis, metastasis and activation of other signaling
networks (Reuter et al., 2010). Another redox stress sensitive cascade includes the PP1JNK-Sp1 signaling pathway (Chu and Ferro, 2006; Ryu et al., 2003). Following activation
via phosphorylation, the transcription factor Sp1 is translocated to the nucleus and binds
GC-rich motifs of promoters augmenting transcription of genes relevant for stress
responses (Ryu et al., 2003), cellular differentiation (Gong et al., 2014), proliferation
(Zhang et al., 2014). Interestingly, galectins-1, -3, -10 and -12 have been reported to
contain multiple potential Sp1 binding sites in their promoter region: indicating a common
redox-sensitive regulatory factor and the potential for expression of these galectins to be
influenced by oxidative stress (Dyer and Rosenberg, 2001; Hotta et al., 2001).
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Figure 3. Redox sensitive PP1-JNK-Sp1 signaling pathway. Hydrogen peroxide
inhibits PP1, which leads to the phosphorylation and subsequent activation of the Sp1
transcription factor. Inducer of reactive oxygen species – menadione – is proposed to
increase galectin gene expression via JNK signaling and Sp1 activation/binding.
The above schematic demonstrates the PP1-JNK-Sp1 signaling pathway (interpreted from
Chu and Ferro [2006]). Many galectin promoter regions have potential Sp1 binding sites
and therefore this transcription factor is proposed in regulating galectin transcript
expression.
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Only recently, have galectins been analyzed more critically regarding their involvement
with oxidative processes, redox status and related signaling mechanisms. Although many
galectins share high sequence homology indicating similar biological function, there
appears to be different regulatory mechanisms controlling their expression. This level of
complexity makes it difficult to discern the precise function of each galectin across many
cell types and conceptually as a whole considering there is often galectin functional
redundancy.

1.4.1

Galectin-1 – role in oxidative stress

Galectin-1 is expressed in many tissues, primarily of mesodermal origin including: skeletal
and smooth muscle, heart, liver, lung, spleen, kidneys and others (Klyosov, 2008). As
mentioned previously galectin-1 has been reported to be redox-sensitive whereby its
structure and subsequent function is altered via oxidation of free cysteine residues. This
potentially explains why galectin-1 is mitogenic for various human cells including lymph,
vascular and liver cells, while being an inhibitor of cell growth in neuroblastoma and
connective tissue of bone marrow (Camby et al., 2006). A specific example includes
oxidation of the three intramolecular disulfide bonds of galectin-1 allowing for a gain of
CRD-independent effects leading to increased axonal regeneration in peripheral nerve but
at the same time losing lectin binding associated functionality (Inagaki et al., 2000). A
similar effect is demonstrated by Yu et al. (2015) whereby exogenously added oxidized
human galectin-1 confers resistance toward oxidative stress in Molt4 cells compared to the
reduced form of this galectin (Yu et al., 2015). Further, mouse galectin-2 is susceptible to
oxidation by ROS resulting in loss of CRD-dependent function (Tamura et al., 2015).
These data indicate that the manner in which galectin-1 confers its resistance may be
dependent on its redox state.
Aside from galectin-1 being structurally affected by the redox environment, this protein
can also play a direct role in various oxidative processes. In fact, early studies demonstrated
the potency of human and animal galectin-1, in addition to other galactoside-specific
lectins to induce a respiratory burst from neutrophils (Timoshenko and Gabius, 1993;
Timoshenko et al., 1997). Elola et al. (2005) reported that exogenously added pig spleen
galectin-1 to white blood cells was able to activate polymorphonuclear leukocytes (PMN)
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to produce significant levels of O2•- when combined with other priming agents (Elola et
al., 2005). Similarly, galectin-1 alone is able to activate extravasated human neutrophils to
produce significant levels of O2•-. Lin et al. (2015) demonstrated that galectin-1 can
produce ROS by activating NADPH oxidase, which is important for wound healing in
myofibroblasts (Lin et al., 2015). Interestingly, galectin-1 has been shown to promote
angiogenesis and protect cancer cells from oxidative stress in a CRD-dependent fashion,
which is attenuated by the disaccharide thiodigalactoside (TDG) (Ito et al., 2011).
In addition to direct redox interactions, galectin-1 has also been reported playing a role
within various oxidative stress/redox-sensitive signaling pathways. One example includes
the interaction between galectin-1 and transforming growth factor (TGF-β). This growth
factor is able to promote ROS by activating NADPH oxidase (Thannickal et al., 1998), and
has been found to increase galectin-1 expression in a dose dependent manner (Daroqui et
al., 2007). Further, galectin-1 has been reported to increase p38 and ERK expression in
vitro (Chung et al., 2012; Maeda et al., 2004). Similarly, galectin-1 gene expression is
down-regulated through the redox-sensitive ERK pathway evident by inhibition of
MEK1/2 with inhibitors U0126 and SB202190 in activated T-cells (Fuertes et al., 2004).
These findings show how galectin-1 expression is affected by both up- and down-stream
components of these MAPK pathways. mTOR signaling is also oxidative stress sensitive
(Heberle et al., 2015), and its downstream target molecule, P70S6 has been shown to
increase galectin-1 expression (Fuertes et al., 2004). Galectin-1 has been shown to activate
the JNK/c-Jun/AP-1 signaling pathway leading to apoptosis in T-cells (Brandt et al., 2010).
This apoptotic effect was attenuated with the inhibitor SP600125, however, the role of JNK
signaling on regulating galectin-1 gene expression has yet to be demonstrated. Evidence
suggests JNK as a potential mediator of galectin-1 expression given its strong association
with T-cell apoptosis (Zhu et al., 1999), and oxidative stress (Wang et al., 2008).
Considering the strong association between oxidative stress and the pathogenesis of many
diseases, galectin-1 is suggested as being a strong candidate biomarker of various stress
responses. The interaction between galectin-1 and different signaling pathways suggest this
protein as a major player within develop of diseases and its importance in mediating gene
transcription of factors relevant for host defenses.
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1.4.2

Galectin-3 – role in oxidative stress

The role of galectin-3 regarding oxidative processes has been well documented. In fact,
galectin-3 has been listed as a biomarker for many different diseases/conditions implicated
with oxidative stress including thrombosis (Madrigal-Matute et al., 2014), heart failure
(Erkilet et al., 2013; Medvedeva et al., 2016), various cancers (breast, kidney, thyroid and
prostate) (Balan et al., 2012; Idikio, 2011), cardiac fibrosis (Martínez-Martínez et al.,
2014), and Alzheimer’s disease (Wang et al., 2015). It is no wonder then, why galectin-3
is well studied considering its appeal across so many clinical paradigms.
Similar to galectin-1, exogenously administered galectin-3 is also able to promote
superoxide production by human neutrophils demonstrating the direct role of this galectin
in oxidative processes (Almkvist et al., 2001; Karlsson et al., 1998). This oxidative burst
by human neutrophils is induced following galectin-3 binding primarily the receptors
CD66a and CD66b (Feuk-Lagerstedt et al., 1999). A similar effect has been demonstrated
in mast cells whereby galectin-3 promotes oxidative stress-induced mast cells death via a
CRD-dependent mechanism (Suzuki et al., 2008). Interestingly, this effect could not be
replicated by galectin-1, indicating glycoreceptor-specific affinities for different galectin
isoforms; dependent on cell type. Interestingly, galectin-3 has also been shown to
potentially attenuate superoxide production via downregulation of priming factors
suggesting that the specific role of this protein in either eliciting or inhibiting oxidative
burst is cell context dependent (Cortegano et al., 1998).
Galectin-3 regulation of and by redox signaling pathways has also been characterized. The
promoter region of LGALS3 contains several regulatory elements including binding sites
for AP-1 and NF-ĸB (Vasta and Ahmed, 2009). Interestingly, galectin-3 is has also been
reported to stimulate the ERK/p38 and JNK pathways indicating galectin-3 can regulate
and be regulated by these pathways (Filer et al., 2009). Further, Chen et al. (2006) report
that mice knockout models for galectin-3 show decreased JNK1 protein and mRNA levels
and a concurrent decrease in cytokine production, indicating the potential for galectin-3 to
regulate this pathway at the transcriptional level (Chen et al., 2006).
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1.4.3

Galectins-8, -9, -10 and -12 – role in oxidative stress

Although the literature primarily indicates a strong association between galectins-1 and -3
with oxidative processes and redox regulation, there is evidence of other galectins
participating in these processes.
Galectin-8 has also been shown to elicit superoxide anion production in primed human
neutrophils, both intracellularly and extracellularly in a CRD-dependent manner (Carlsson
et al., 2007). Furthermore, the levels of superoxide production are comparable to that of
the potent chemotactic factor formylmethionyl-leucyl-phenylalanine (fMLP), which often
serves as a positive control for neutrophilic oxidative burst (Nishi et al., 2003). The redoxsensitive factors ERK and Akt act downstream of galectin-8 signal transduction (Romaniuk
et al., 2010); however, the relation of this pathway to galectin-8 is not studied in the context
of cellular stress. Additionally, little is known about the regulatory methods of this galectin
both transcriptionally and translationally in the context of oxidative stress. However, many
transcriptional isoforms of galectin-8 exist indicating the potential involvement of stressdependent splicing mechanisms. Considering widespread galectin-8 cell expression,
further details should be identified for better understanding of this galectins role in a
cellular stress context.
Originally discovered in as a potent eosinophilic chemoattractant, galectin-9 has been
reported as a key regulatory of autoimmune disease, in particular, by shifting both adaptive
and innate immunity to an anti-inflammatory profile (Wiersma et al., 2013). Similar to
galectin-8, galectin-9 is also a tandem-repeat galectin that consists of different spliced
isoforms (Chabot et al., 2002), indicating its potential in having stress dependent splice
variants. Vega-Carrascal et al. (2014) provide the only evidence of ROS production by
human neutrophils, induced by galectin-9. The authors report that while galectin-9 alone
was only able to promote superoxide production at supra-physiological levels, neutrophils
primed prior to exposure to galectin-9 are more sensitive to superoxide production via
NADPH oxidase (Vega-Carrascal et al., 2014). Redox-sensitive pathways have also been
implicated in the regulation of galectin-9, and vice versa. In particular, inhibition of p38,
but not JNK/c-Jun, significantly reduced expression of galectin-9 (Hsu et al., 2015). In
contrast, JNK-induced galectin-9 expression has been detected in astrocytes indicating cell
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type specific galectin-9 regulation (Steelman et al., 2013). Additionally, there is evidence
of JNK pathway activation induced by galectin-9, indicating a role of galectin-9 working
both up- and down-stream of this redox signaling pathway (Kobayashi et al., 2010).
Prototypical galectin-10 has been reported in few molecular processes regarding oxidative
stress and redox signaling. Selective binding preference of mannose by galectin-10 perhaps
indicates receptor specific stress mediation. A deletion of the galectin-10 encoding gene in
Caenorhabditis elegans revealed a protective role of this protein against oxidative stress
(Nemoto-Sasaki and Kasai, 2009). However, no molecular signaling factors regarding
galectin-10 gene expression nor factors impacted by galectin-10 have been identified.
The more recently discovered galectin-12 has also been implicated in oxidative processes.
Involvement of galectin-12 with adipocyte regulation and diminished insulin resistance
suggests this tandem-repeat galectin may be a potential therapeutic target for metabolic
syndrome and related disorders – all of which are highly impacted by elevation in reactive
oxygen species. Unfortunately, few molecular mechanisms regulating or responding to
galectin-12 have been documented. Galectin-12 has been reported to induce adipogenic
signaling through increased expression of C/EBPs (Yang et al., 2004). Interestingly, these
C/EBP transcription factors regulate the ROS producing enzyme NADPH oxidase,
indirectly implicating the association of galectin-12 with oxidative burst (Manea et al.,
2014). Yang et al. (2004) also report galectin-12 expression is upstream of the oxidative
stress sensitive ERK and Akt pathways (Yang et al., 2004). Additionally, ablation of
galectin-12 expression was shown to diminish levels of nitric oxide secretion while
reducing NF-ĸB and AP-1 expression, in macrophages (Wan et al., 2016).

1.5 Cellular differentiation
Cellular differentiation is a developmental process whereby cells become more specialized.
For example, early stem cells may divide further into pluripotent stem cells, which can then
give rise to various cell types within an organism. Mesenchymal stem cells (MSCs) from
the bone marrow give rise to adipocytes and stromal cells (Beyer Nardi and da Silva
Meirelles, 2006) whereas neural stem cells (NSCs) give rise to the nervous system and
differentiate into neurons, astrocytes and other specialized neural cell types (Gage, 2000).
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In particular, embryonic stem cells may further divide into hematopoietic stem cells
(HSCs), which are stem cells that can give rise to over 10 distinct mature blood cell types
through the process of hematopoiesis (Seita and Weissman, 2010). Although
hematopoiesis occurs at embryonic development, this process is still present in adulthood
to replenish the blood system (Jagannathan-Bogdan and Zon, 2013). Blood cells are
divided into three lineages based on their respective differentiation patterns: erythrocytes
consisting of oxygen carrying red blood cells, lymphocytes consisting primarily of T and
B-cells important for immune function and promyelocytes, which give rise to granulocytes
(basophils, eosinophils and neutrophils), and macrophages. Production of fully
differentiated granulocytes and macrophages is dependent on induction by hematopoietic
cytokines (Miranda and Johnson, 2007). Major cytokines responsible for differentiation
primarily consist of colony-stimulating factors (CSFs), which are lineage specific
glycoproteins that function as cytokines and interact with their cognate receptors on the
surface of early progenitor cells within bone marrow (Barreda et al., 2004). Binding of
cytokines to their respective receptors elicits multiple signaling pathways including: p38,
JNK, ERK, JAK/STAT and PI3K/Akt. These pathways then activate transcription factors
such as C/EBPs, cyclins, c-Myc and others relevant for myeloid differentiation (Miranda
and Johnson, 2007). Differentiation is accompanied by selective increased expression of
specific proteins. In particular, p47phox is one of many cytosolic components of
superoxide producing enzyme, NADPH oxidase, that is upregulated in response to
neutrophilic differentiation of HL-60 cells, and can therefore be considered a marker
(Ellison et al., 2015). The expression of NADPH oxidase is important for fully functioning
differentiated HL-60 (Chen et al., 2012). Further, knockout studies of this subunit have
shown to decrease oxidative stress implicating its potential as a marker for both
differentiation and oxidative processes (Landmesser et al., 2002; Pal et al., 2014).
Interestingly, galectins have also been reported in playing a role within hematopoietic
cellular differentiation. In fact, evidence suggests that elevated galectin expression occurs
during the processes of differentiation and may act as a potential secondary mediator
(Acosta-Rodríguez et al., 2004). The involvement of each galectin with differentiation is
discussed below.

26

1.5.1

Galectin-1 – role in cellular differentiation

Galectin-1 gene expression is implicated in myeloid cellular differentiation (Abedin et al.,
2003). Interestingly, the change in galectin-1 gene expression can vary depending on cell
type and the inducer of differentiation. For example, treatment of different cells with
differentiating agents have reported to decrease (Chiariotti et al., 1994), have no effect on
(Abedin et al., 2003) or increase (Ohannesian et al., 1994) galectin-1 expression.
Interestingly, exogenously added recombinant galectin-1 was shown to have a biphasic
effect on hematopoietic cells by augmenting differentiation of promyelocytes into the
granulocytic lineage at a low dose or inhibiting differentiation at a high dose (Vas et al.,
2005). This data indicates the complexity of galectin-1 as the low dose effect was
dependent following CRD binding activity while the high dose was CRD-independent.
Other studies have shown high galectin-1 expression during differentiation of HSCs along
with other well-known factors (Silva et al., 2003).
Although little information is present on regulatory mechanisms associated with galectin1 and hematopoietic cell differentiation; Liu et al. (2008) report that galectin-1 contributes
to thymocyte differentiation and cell fate through transient activation of the ERK pathway
(Liu et al., 2008b). Other results indicate that epigenetic mechanisms may contribute to
galectin-1 expression. Methylation of the galectin-1 promoter at CpG clusters indicates one
molecular mechanism governing modulation over the transcriptional activity of the
galectin-1 gene (Benvenuto et al., 1996). Interestingly, inhibitors of DNA
methyltransferases including 5-azacytidine (AzaC), and the less toxic 5-aza-2’deoxycytidine (decitabine) have been shown to increase cellular differentiation via removal
of methyl groups on candidate promoters (Borodovsky et al., 2013; Turcan et al., 2013). In
fact, lymphocytes treated with AzaC show a concomitant increase in galectin-1 gene
expression followed by induction of hematopoietic cellular differentiation (Poirier et al.,
2001).

1.5.2

Galectin-3 – role in cellular differentiation

One unique feature of galectin-3 is its involvement in regulating cellular differentiation.
This chimeric galectin mediates cellular differentiation of the hematopoietic lineage,
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during both myeloid (Abedin et al., 2003), and lymphoid (Oliveira et al., 2009)
hematopoiesis. Generally, it has been shown that endogenous levels of galectin-3 are
strongly upregulated on the cell surface, binding primarily CD34, during myeloid cell
differentiation (Le Marer, 2000). Increased galectin-3 expression has been observed during
monocytic differentiation by human promyelocytes (Abedin et al., 2003), primary human
monocytic differentiation into macrophages (Liu et al., 1995), and during T-cell
differentiation (Vasil’eva et al., 2013). However, galectin-3 has also been shown to directly
inhibit differentiation in non-hematopoietic cell types (Nakajima et al., 2014) making the
function of this galectin during differentiation cell context dependent. In particular,
differentiation of dendritic-cells decreased galectin-3 expression (Dietz et al., 2000). These
opposing findings make galectin gene expression difficult to utilize as prognostic markers
of general cell function (in this case differentiation). More evidence is needed to understand
the role of galectin expression in response to or as possible mediators of differentiation.
Galectin-3 has also been reported to be a regulator of differentiation. It’s
expression/function directly inhibits osteoblast differentiation (Nakajima et al., 2014)
while augmenting oligodendrocyte differentiation (Pasquini et al., 2011). Similarly,
galectin-3 has been reported to inhibit granulocyte-macrophage colony stimulating factor,
a cytokine important for inducing early stages of differentiation (Krugluger et al., 1997).
In fact, the expression of galectin-3 may not only be important for inducing/augmenting
differentiation into specific lineages: but by also inhibiting differentiation into other final
cell fates. Acosta-Rodríguez et al. (2004) provide one example whereby knockdown of
galectin-3 not only induced B-cell differentiation but also reduced the percentage of plasma
cell differentiation (Acosta-Rodríguez et al., 2004). The opposing effects of galectin-3
demonstrate its complexity during hematopoietic cellular differentiation and potential to
be regulated by different networks suggesting different cell types maintain different
regulatory methods for mediating galectin-3 expression.
Epigenetic regulation has also been reported for galectin-3. Malignant prostate epithelial
cells were shown to be sensitive to AzaC treatment displaying a marked increase in
galectin-3 gene expression that was not seen within benign and malignant tissue (Ahmed
et al., 2007). Similarly, various CpG islands within the transcription start site of the
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LGALS3 gene suggest that the DNA methylations state of the galectin-3 gene is a potential
biomarker for cancer (Keller et al., 2013; Ruebel et al., 2005).

1.5.3

Galectins-8, -9, -10 and -12 – role in cellular differentiation

Despite there being substantially less data on the galectins-8, -9, -10 and 12, there is
literature indicating their involvement with differentiation.
Similar to galectin-3, galectin-8 is able to promote T-cell differentiation by modulating
cytokine activity through TGF-β signaling (Sampson et al., 2016). Although there is little
literature on the involvement with galectin-9 and cellular differentiation, there is some
evidence of transcript downregulation during monocytic differentiation (Abedin et al.,
2003). In contrast, upregulation of galectin-9 mRNA during monocytic differentiation has
been reported making the role of this galectin during differentiation unclear (Harwood et
al., 2016). Unrelated to hematopoietic differentiation, galectin-9 promotes MSC
differentiation into chondrocytes through TGF-β signaling (Arikawa et al., 2009).
Abedin et al. (2003) also reported an increase in galectin-10 transcript levels following
neutrophilic differentiation of promyelocytes in vitro despite this galectin being expressed
predominately in eosinophils (Abedin et al., 2003). Knockdown of galectin-10 expression
during differentiation of eosinophil progenitors significantly inhibited granulogenesis
indicating a novel role for galectin-10 during eosinophil development (Doyle and
Ackerman, 2009). This galectin has large sequence and structure homology to galectins-1
and -3 suggesting that it may also play a prominent role in hematopoietic cell
differentiation (Ackerman et al., 1993).
Galectin-12 has been reported in playing contrasting roles during cell differentiation. In
particular, galectin-12 expression promotes adipocyte differentiation (Yang et al., 2004)
while inhibiting neutrophilic differentiation of promyelocytes (Xue et al., 2016).
Interestingly, however, ablation of galectin-12 in bone marrow cells did not affect their
capability in differentiating into macrophages indicating the redundant function of other
galectins in myeloid cell differentiation (Wan et al., 2016). Various factors thought to be
involved with galectin-12 during cellular differentiation include vacuolar protein sorting
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13 homolog C (VPS13C), C/EBP transcription factors and ERK1/2 pathways effecting NFĸB and AP1 (Wan et al., 2016; Yang et al., 2004, 2016).

1.6 Hypothesis
The existing literature shows contrasting roles for galectins during cell differentiation and
in response to oxidative stress. Interestingly, many of these galectins are expressed within
certain tissue/cell types and most studies typically only examine a single galectin.
Therefore, understanding galectin family expression patterns/profiles across different
tissues is important for elucidating the overall synergistic, additive or antagonistic
functions of galectins. Further, often altered galectin expression patterns are observed in
response to different types of cell stress including: oxidative stress, hypoxia, nutrient
deprivation, radiation and others (reviewed in Timoshenko, 2015). These findings suggest
an importance of galectins in response to many types of pathological stress positioning
galectins as possible therapeutic intervention targets. The overarching goal of my study is
determine if galectins may be used as biomarkers of different types of cellular stress found
within the tumour microenvironment by comparing galectin expression profiles in a
leukemic cell line.
The Timoshenko lab has recently demonstrated that the human promyelocytic leukemic
HL-60 cell line is an excellent model to investigate stress-sensitive galectins (Timoshenko
et al., 2016). HL-60 cells express 6 of the 12 known mammalian galectins and are easily
differentiated in neutrophils when exposed to dimethyl sulfoxide (DMSO). My study
specifically aims to identify the galectin expression profile of HL-60 cells exposed to both
oxidative stress and DMSO-induced neutrophilic differentiation in an effort to establish a
link between these two processes and identify potential molecular mechanisms responsible.
Interestingly, Ogino et al. (2010) have reported that H2O2 is able to enhance neutrophilic
differentiation of HL-60 cells despite not investigating any molecular mechanisms
potentially responsible (Ogino et al., 2010). Thus altered expression of galectins in
response to either oxidative stress or during differentiation may reveal overlapping
regulatory mechanisms of galectin expression.

30

I hypothesize that oxidative stress responsive galectins are involved with HL-60 cell
neutrophilic differentiation. The rationale behind this study is that both oxidative stress
and cell differentiation are capable of producing altered galectin expression profiles.
Objective 1: to determine the galectin expression profile of HL-60 under menadioneinduced oxidative stress and DMSO-induced neutrophilic differentiation. This will be done
by RT-qPCR and immunoblotting techniques.
Objective 2: To investigate the effect of galectin inhibitors on HL-60 cellular proliferation
and neutrophilic differentiation. This will be done by determining the cell population
doubling time through direct counts. Neutrophilic differentiation will be determined using
a spectrofluorometric assay used to measure ROS production.
Objective 3: To investigate the effect DNA methyltransferase inhibition and JNK signaling
on galectin expression and during oxidative stress and neutrophilic differentiation. This
will be done by RT-qPCR and immunoblotting techniques.
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Chapter 2

2

Materials and methods

2.1 Cell culture
Human promyelocytic leukemia suspension cell line HL-60 (ATCC® CCL240™) was
obtained from ATCC. Cells were cultured in Iscove’s Modified Dulbecco’s Eagles medium
(IMDM) (Corning™) supplemented with 10% charcoal stripped fetal bovine serum (FBS)
(Wisent Bioproducts), 100 IU/mL penicillin, 100 μg/mL streptomycin, in a humidified
incubator at 37°C and 5% CO2. Cells were maintained under confluent conditions (1x106
cells/mL) for all treatments and passaged accordingly. Cell viability was determined using
a Leitz Z0124 microscope using a trypan blue (0.2%) exclusion test.

2.2 Cell treatments
To induce oxidative stress, HL-60 cells were treated with 10 μM menadione sodium
bisulfite (Sigma-Aldrich) or 100 μM CoCl2 (Sigma-Aldrich) for 24 hrs. HL-60 neutrophilic
differentiation was accomplished by treating cells with 1.3% DMSO for 72 hrs unless
otherwise stated. Either 1 or 2.5 mM NAC (Sigma-Aldrich) was administered as an
antioxidant for 24 hrs and 72 hrs for either oxidative stress or differentiation experiments,
respectively. Global hypomethylation was accomplished using 50 nM DNA
methyltransferase inhibitor 5-aza-2’-deoxycytidine (decitabine; Cayman Chemical) for 72
hrs. Treatment with NAC or decitabine for 72 hrs included treating 3 times every 24 hrs
from initial passage. Inhibition and activation of JNK was accomplished using 25 μM
SP600125 (LG Labs), and 400 nM anisomycin (StressMarq), respectively for 24 hrs.
Galectin inhibitors used included lactose (Sigma-Aldrich), N-acetyl-D-lactosamine
(LacNac; Carbosynth), thiodigalactoside (TDG; Carbosynth), and galectin-1 specific
inhibitor OTX008 (Axon Medchem). Mannose (Sigma-Aldrich), and α-methyl-Dmannoside (α-MM; Sigma-Aldrich) were used as non-inhibitory sugars except for their
specific affinity to galectin-10.
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2.3 RNA extraction and cDNA synthesis
Following cell treatment, cells were centrifuged and resuspended in Dulbecco’s PhosphateBuffered Saline (DPBS) without Ca2+ and Mg2+. Cells were then centrifuged, lysed with
TRIzol® (Ambion), and RNA was isolated according to the manufacturer’s protocol. RNA
was dissolved in water and quantified using a NanoDrop 2000c UV-Vis spectrophotometer
(Thermo Fisher). Purity was assessed considering A260/280 of > 1.8 as the threshold. cDNA
was reverse transcribed from 2 µg of RNA using the Maxima First Strand cDNA Synthesis
Kit for RT-qPCR (K1671; Thermo Fisher) according to the manufacturer’s protocol. All
primers were synthesized by BioCorp UWO OligoFactory (Western University,
Department of Biochemistry).

2.4 RT-PCR and RT-qPCR
Primer information including sequence, amplicon size, cycling conditions and referencing
is located in Appendix A: supplementary material. RT-PCR reaction mixtures consisted of
2X Taq master mix (FroggaBio) mixed with nuclease–free water, 800 nM forward primer,
800 nM reverse primer and 1 µL of cDNA template diluted 25 times. RT-PCR products
were separated on a 2% agarose gel made with a 40 mM Tris, 20 mM acetic and 1 mM
EDTA (TAE). Nucleic acids were stained using SYBR® Safe (Invitrogen), and imaged
using a ChemiDoc XRS system (Bio-Rad).
RT-qPCR for relative mRNA transcript levels were quantified using a SensiFAST™
SYBR® No-ROX Kit (Bioline) mixed with nuclease–free water, 400 nM forward primer,
400 nM reverse primer, 0.5 µL of undiluted cDNA template and amplified with a CFX96™
Real-Time PCR Detection System (Bio-Rad). Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) was used as an internal control. Quantification of relative fold transcript levels
was calculated using Livak’s 2-ΔΔCt or Pfaffl methodology to predict accurate gene
expression levels based on realistic PCR amplification efficiencies. RT-qPCR using the
Oxidative Stress RT2 Profiler PCR Array (PAHS-065Z; Qiagen) was performed as
described by the manufacturer.
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2.5 Antibodies
Primary antibodies listed below were diluted in 50 mM Tris, 150 mM NaCl and 0.05%
Tween-20 (TBS-T) supplemented with 5% bovine serum albumin (BSA), and 0.05%
sodium azide. For western blotting purposes, the following primary antibodies were used:
galectin-1 (1:200; sc-28248; Santa Cruz), galectin-3 (1:200; sc-20157; Santa Cruz),
galectin-10 (1:10,000; ab-157475; AbCam), galectin-12 (1:200; sc-67294; Santa Cruz),
SAPK/JNK (1:1000; 9252; Cell Signaling Technology), Phospho-SAPK/JNK (1:1000;
9251; Cell Signaling Technology), and β-actin (1:200; sc-47778; Santa Cruz). Secondary
antibodies include anti-rabbit IgG-HRP (1:10,000; sc-2004; Santa Cruz), and anti-mouse
IgG HRP (1:10,000; sc-2005; Santa Cruz).

2.6 Protein isolation and western blotting
Following cell treatment, cells were centrifuged and resuspended in DPBS. Cells were then
homogenized in a 2% SDS extraction buffer containing 50 mM Tris pH 7.5 supplemented
with 1 mM PMSF and protease inhibitor cocktail containing 1 mM AEBSF, 5 mM EDTA,
50 µM leupeptin and 1 µM pepstatin. Samples were then incubated on ice for an additional
10 minutes before further homogenization via sonication with a Microson™ XL-2000
Ultrasonic Liquid Processor (Qsonica) for 15 seconds at amplitude setting 2. Total protein
concentration was determined using the DC Protein Assay™ (5000111; Bio-Rad) as per
the manufacturer’s protocol and absorbance was measured at 595 nm by a Model 3550
Microplate Reader (Bio-Rad). Protein extract (25 μg) was resolved by 15% SDS-PAGE
and transferred onto PVDF membrane (Bio-Rad). Membranes were blocked with 5% BSA
and 1% milk in TBS-T at room temperature for 1 hr before being probed with primary
antibody overnight at 4°C. Membranes were then incubated with an appropriate
horseradish peroxidase-conjugated secondary antibody (Santa Cruz), amplified with
SuperSignal™ West Pico Chemiluminescent Substrate (34080; Thermo Fisher), and
imaged with a ChemiDoc XRS system (Bio-Rad). Densitometry was performed using
Image Lab™ software and significant differences were determined using SPSS considering
p < 0.05 as the statistical threshold.
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2.7 Measurement of fMLP-induced ROS production
Cells were seeded at 0.5x106 cells/mL in 24 well plates and treated with 1.3% DMSO for
72 hrs in order to achieve fully neutrophil-like differentiated HL-60 cells. Cells were then
collected, centrifuged and resuspended in Hanks’ Balanced Salt Solution (HBSS) prewarmed to 37°C. Cells were loaded into a cuvette and absorbance was read at 600 nm in
order to standardize cell concentration using NanoDrop 2000c spectrophotometer (Thermo
Fisher). The cuvette was then loaded into an AMINCO-Bowman Series 2 Luminescence
Spectrometer reading excitation and emission wavelengths at 380 and 460 nm,
respectively. Cells were then exposed to 1 μM scopoletin (Sigma-Aldrich); a fluorescent
substrate for 20 μg/mL horseradish peroxidase (HRP; Sigma) that is oxidized into nonfluorescent products. A “cocktail” containing scopoletin and HRP was then added to the
cuvette; producing fluorescence until a stable level is observed. To induce oxidative burst,
100 nM fMLP was added to the cuvette. Scopoletin oxidation was measured as a decrease
in fluorescent intensity. The subsequent kinetic data points were run through R using the
algorithm described in Appendix A: Supplementary material to determine the point at
which the slope (rate of H2O2 production) is greatest. Rate of H2O2 production was
calculated as the maximal slope of recorded traces of scopoletin oxidation normalized to
cell concentration and original fluorescent maximum (Fmax) presented as pmol/sec/1x106
cells.

2.8 Microscopy and nuclei staining
HL-60 cell cultures were observed and imaged using an inverted Leica DM IL LED
microscope in integrated modulation contrast (IMC) mode. To investigate cell nuclei,
cytospins were prepared. Firstly, cells were resuspended in IMDM at 0.5x106 cells/mL,
then centrifuged onto glass slides for 4 mins at 500 rpm using a Shandon’s Cytocentrifuge
2. Cells were then fixed for 10 minutes using methanol and nuclei staining was performed
using 2 µg/mL Hoechst-33342. Imaging of segmented nuclei to confirm cellular
differentiation was done using an AxioImager A.1 fluorescent microscope (Carl Zeiss),
and images were taken with a CCD camera Model XCD-X700 (Sony) using Northern
Eclipse 8.0 software (Emprix Imaging Inc.). Scale bars were added using Northern Eclipse
8.0 software.
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2.9 Cell proliferation assay
Cells were seeded at 0.1x106 cells/mL in 24 well plates and treated with different galectin
inhibitors at various concentrations for 96 hrs. Cell count and viability were determined
using a Leitz Z0124 microscope and using a trypan blue (0.2%) exclusion test every 24
hours from initial seeding in order to determine cell doubling time.

2.10 Statistical analysis
All experiments were performed in at least triplicate unless otherwise stated and data are
expressed as mean ± SD (unless stated otherwise). A one-way analysis of variance
(ANOVA) followed by a Tukey’s HSD test were used to determine statistical significant
differences across means. An independent samples t-test was used to compare means of
treated groups vs. their respective control. Correlation analysis between genes was
performed using a Pearson’s correlation test. Significant differences were determined using
SPSS and GraphPad Prism 7 software considering p < 0.05 as the statistical threshold.

36

Chapter 3

3

Results

3.1 The galectin expression profile was differentially
regulated in response to menadione-induced oxidative
stress
To determine the galectin expression profile, end-point PCR was performed to amplify 6
of the 12 known human galectin genes expressed in HL-60 cells (Figure 4) (for reference
see Appendix A: Supplementary material). The galectin mRNA expression profile was
then determined for HL-60 cells treated with oxidative stress inducers: 10 μM menadione
with or without 1 mM NAC and 100 μM CoCl2 for 24 hrs, using RT-qPCR (Figure 5).
There was a statistically significant difference between treatment groups as determined by
one-way ANOVA for LGALS1 (F4,1 = 21.6, p < 0.001), LGALS3 (F4,1 = 139.14, p < 0.001),
LGALS9 (F4,1 = 13.77, p < 0.001), LGALS10 (F4,1 = 11.93, p < 0.01), and LGALS12 (F4,1 =
8.74, p < 0.01). CoCl2 significantly increased LGALS1 (p < 0.05), and LGALS10 (p < 0.05)
transcript expression only (Figure 5A, E) while significantly decreased (p < 0.001)
expression of LGALS9 (Figure 5D). Similarly, transcript expression of LGALS1, LGALS3
and LGALS10 was significantly up-regulated (p < 0.01, p < 0.001, p < 0.01 respectively)
in response to menadione (Figure 5A, B, E), which was attenuated by the antioxidant NAC.
Similar to the effect of CoCl2, menadione significantly decreased (p < 0.01) LGALS9
expression that was also rescued by the addition of NAC (Figure 5D). Although treatment
with menadione did not significantly increase LGALS12 transcript expression relative to
the control; expression between menadione alone and menadione with NAC, was
significantly different (p < 0.05) (Figure 5F), similar to the trend seen with LGALS1,
LGALS3 and LGALS10. Interestingly, no significant differences in LGALS8 transcript
levels were noticed across all treatments (F4,1 = 0.79, p > 0.05).

37

L

300bp –
200bp –
100bp –

1

2

3

4

5

6

7

38

Figure 4. Verification of galectin gene PCR amplicons following RT-PCR by agarose
gel electrophoresis.
PCR products were resolved by a 2% agarose gel via electrophoresis and visualized by
SYBR® Safe staining. Amplified products were of the expected sizes. Lane L (ladder), lane
1 (LGALS1, 220 bp), lane 2 (LGALS3, 108 bp), lane 3 (LGALS8, 172 bp), lane 4 (LGALS9,
91 bp), lane 5 (LGALS10, 82 bp), lane 6 (LGALS12, 111 bp), and lane 7 (GAPDH, 95 bp).
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Figure 5. Oxidative stress altered HL-60 galectin transcript levels.
∆∆Ct relative galectin transcript expression in HL-60 cells treated with 100 µM CoCl2, 10
µM menadione and/or 1 mM NAC for 24 hrs relative to untreated cells, using RT-qPCR.
(A) LGALS1, (B) LGALS3, (C) LGALS8, (D) LGALS9, (E) LGALS10 and (F) LGALS12.
GAPDH was used as an internal control. The data represent the mean ± SD, n = 3-6.
Significant differences among treatments were determined using ANOVA followed by a
Tukey’s HSD test considering *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 6. Oxidative stress altered HL-60 galectin protein levels.
Immunoblot for galectin protein expression in (A) HL-60 cells treated with 10 µM
menadione and/or 1 mM NAC for 24 hrs. Quantification of (B) galectin-1, (C) galectin-3,
(D) galectin-10 and (E) galectin-12 protein levels by densitometric analysis of the
immunoblot in (A). β-actin was used as a loading control. 25 μg of protein were loaded per
well. The data represent the mean ± SD, n = 3. Significant differences among treatments
were determined using ANOVA followed by a Tukey’s HSD test considering *p < 0.05,
**p < 0.01, ***p < 0.001.
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Figure 7. Expression profiling of oxidative stress markers in HL-60 cells following
menadione exposure.
Cells were treated with 10 µM menadione for 24 hrs. (A) Oxidative Stress RT2 Profiler
Array Kit using RT-qPCR. The data represent relative fold transcript levels (2-ΔΔCt) of 84
genes (only candidate genes are shown) sensitive to oxidative stress, n = 1. (B) RT-qPCR
for oxidative stress marker, p47phox, expression following treatment with 10 µM
menadione for 24 hrs, relative to control cells. GAPDH was used as an internal control.
The data is presented as the mean ± SD n = 3. *p < 0.05, **p < 0.01, ***p < 0.001. (C) Gel
electrophoretic analysis of RT-PCR product for oxidative stress marker ho-1 (220 bp).
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To confirm differences observed at the transcript expression, western blotting was
performed to analyze protein levels (Figure 6). Significant differences were determined
after densitometry analysis of bands. There was a statistically significant difference
between treatment groups as determined by one-way ANOVA for galectin-3 protein levels
(F3,1 = 25.44, p < 0.001), only. Densitometry analyses revealed a significant increase (p <
0.001) in galectin-3 expression, which was attenuated by NAC exposure (Figure 6C). No
significant differences were observed with galectin-1 (F3,1 = 1.64, p > 0.05) galectin-10
(F3,1 = 1.3, p > 0.05), and galectin-12 (F3,1 = 0.9, p > 0.05) (Figure 6B, D, E).
To further determine the menadione-induced oxidative stress response, RNA from HL-60
cells treated with 10 μM menadione was analyzed using an RT-qPCR array kit for 84 genes
related to oxidative stress (Figure 7). From this array, ho-1 and neutrophil cytosolic factor
1 (p47phox) were picked as strong oxidative response candidates. ho-1 is a classic
antioxidant protein product that cleaves heme while p47phox – typically a marker of
oxidative stress – is more classically known as a marker of cellular differentiation. HL-60
cells treated with 10 μM menadione exhibited p47phox expression as detected by RT-qPCR
(Figure 7B). Gel electrophoresis following RT-PCR revealed a ho-1 amplicon of the
correct size (Figure 7C), indicating that menadione-induced oxidative stress in HL-60 cells.

3.2 The galectin expression profile was differentially
regulated in response to DMSO-induced HL-60
neutrophilic differentiation.
Before determining the galectin expression profile for differentiated HL-60 cells, the
neutrophilic phenotype was first confirmed. In order to differentiate HL-60 cells into
neutrophil-like cells, cells were treated with 1.3% DMSO for 72 hrs. Differentiation was
confirmed using 3 different techniques. Firstly, the rate of H2O2 production and cell
viability was plotted versus time for 6 days (Figure 8A). Following cellular differentiation,
HL-60 expresses fMLP receptors that bind fMLP subsequently activating oxidative burst,
which was measured using a fluorometer. An increase and saturation of H2O2 production
was observed at day 3 while cell viability remained ~80% (Figure 8A). Differentiation was
further confirmed using both: 2 µg/mL Hoechst staining for segmented nuclei,
characteristic of neutrophils (Campbell et al., 1995), and by inverted light microscopy to
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reveal smaller cell and more rounded cell morphology (Figure 8B). Both smaller/rounded
cells and multi-lobed nuclei were visible following 5 day exposure to 1.3% DMSO:
indicative of cellular differentiation (Figure 8B). Finally, RT-qPCR analyses of the
differentiation marker p47phox (Ellison et al., 2015) following 3 day treatment with 1.3%
DMSO revealed a significant increase (p < 0.01) in transcript expression. These three
techniques indicated prominent cellular differentiation following at least 72 hr exposure to
1.3% DMSO.
Following 72 hr treatment with 1.3% DMSO total RNA was isolated and analyzed for
galectin transcript expression using RT-qPCR (Figure 9). There was a statistically
significant difference between treatment groups as determined by one-way ANOVA for
LGALS1 (F3,1 = 10.337, p < 0.01), LGALS3 (F3,1 = 76.5, p < 0.001), LGALS9 (F3,1 = 9.99, p
< 0.01), LGALS10 (F3,1 = 75.69, p < 0.001), and LGALS12 (F3,1 = 16.16, p < 0.001). A
significant increase in LGALS3 (p < 0.001), and LGALS10 (p < 0.001) (Figure 9B, E)
transcript expression during differentiation was observed while LGALS12 (Figure 9F) was
significantly downregulated (p < 0.01) compared to control cells. Interestingly, NAC
partially attenuated DMSO-induced LGALS3 and LGALS10 transcript expression (p <
0.001 and p < 0.01, respectively) (Figure 9B, E), indicating a redox dependent component
during cell differentiation, which subsequently impacts galectin transcript expression.
Similar to the result observed during oxidative stress; no significant differences were
detected across all treatments for LGALS8 (F3,1 = 2.76, p > 0.05). Interestingly, LGALS1
expression was significantly upregulated (p < 0.01) while LGALS9 expression was
significantly downregulated (p < 0.01) when both 1.3% DMSO and NAC were
administered together, however, induced no significant expression changes when either
treatment was added alone (Figure 9A, D).
To confirm differences seen at the transcript levels, western blotting was performed against
individual galectins to analyze protein levels following 72 hr treatment with 1.3% DMSO
(Figure 10). There was a statistically significant difference for galectin-1 (F3,1 = 12.01, p <
0.01), galectin-3 (F3,1 = 103.41, p < 0.001), galectin-10 (F3,1 = 47.59, p < 0.001), and
galectin-12 (F3,1 = 7.36, p < 0.05) between treatment groups as determined by one-way
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Figure 8. Confirmation of DMSO-induced neutrophilic differentiation in HL-60 cells.
Verification of HL-60 cell differentiation induced by 1.3% DMSO through: (A) fMLP
induced H2O2 production 72 hrs post treatment, (B) cell morphology (upper panels), and
nuclei staining (lower panels) with 2 µg/mL Hoechst of HL-60 control cells plated for 24
hrs vs HL-60 cells following treatment with 1.3% DMSO for 120 hrs. Scale bars, 100 µm
(light microscopy), and 25 µm (fluorescent microscopy). (C) RT-PCR and (D) RT-qPCR
for differentiation marker, p47phox (93 bp) following treatment with 1.3% DMSO for 72
hrs. GAPDH was used as an internal control. The data represent the mean ± SD, n = 3.
Significant differences among treatments were determined using an independent samples
t-test considering *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 9. Neutrophilic differentiation of HL-60 cells induced altered galectin
transcript levels.
∆∆Ct relative galectin transcript expression in HL-60 cells treated with 1.3% DMSO and/or
2.5 mM NAC for 72 hrs relative to untreated cells, using RT-qPCR. (A) LGALS1, (B)
LGALS3, (C) LGALS8, (D) LGALS9, (E) LGALS10 and (F) LGALS12. GAPDH was used
as an internal control. The data represent the mean ± SD, n = 3-5. Significant differences
among treatments were determined using ANOVA followed by a Tukey’s HSD test
considering *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 10. Neutrophilic differentiation of HL-60 cells induced altered galectin
protein levels.
Immunoblots for galectin protein expression in (A) HL-60 cells treated with 1.3% DMSO
and/or 2.5 mM NAC for 72 hrs. Quantification of (B) galectin-1, (C) galectin-3, (D)
galectin-10 and (E) galectin-12 protein levels by densitometric analysis of the immunoblot
in (A). β-actin was used as a loading control. 25 μg of protein were loaded per well. The
data represent the mean ± SD, n = 3. Significant differences among treatments were
determined using ANOVA followed by a Tukey’s HSD test considering *p < 0.05, **p <
0.01, ***p < 0.001.
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ANOVA. DMSO-induced neutrophilic differentiation significantly increased protein
levels of galectins-1, -3, and -10 (p < 0.05, p < 0.001 and p < 0.01, respectively) (Figure
10B, C, D) while significantly decreasing galectin-12 protein levels (p < 0.05) (Figure
10E). Interestingly, only galectin-3 levels (Figure 10C) showed significant partial
attenuation (p < 0.05) whereas the other galectins showed no attenuation.

3.3 Inhibition of galectins suppressed cell proliferation and
differentially affected neutrophilic differentiation of HL-60
cells.
To determine the effect galectins have on cellular proliferation of HL-60, competitive
inhibition of galectins was achieved using both non-specific and specific CRD binding
galectin inhibitors – using direct counts of cells in suspension cell culture (Figure 11).
Inhibitors used included: lactose, LacNac, lactobionic acid, TDG, and OTX008. In
addition, α-MM and mannose were used as negative controls considering these sugars are
absent of β-galactosyl residues. There was a statistically significant difference between
treatment groups for TDG (F4,1 = 12.6, p < 0.001), and OTX008 (F3,1 = 11.53, p < 0.001).
Treatment with 40 mM TDG (p < 0.001), and 2.5 (p < 0.05) or 5 μM OTX008 (p < 0.001)
significantly decreased HL-60 cell proliferation indicated by increased cell doubling times
(Figure 11E, F). Although treatments with other inhibitors did not significantly slow cell
proliferation, values showed a trend toward increased doubling time (Figure 11A, B, C,
D). Inhibitors used at the indicated concentrations had no significant effect on cell viability
Treatment with the same inhibitors was used to determine the role of galectins during
neutrophilic differentiation (Figure 12) measured as the fold change in fMLP induced rate
of H2O2 production. Cells were incubated with both differentiation agent 1.3% DMSO for
72 hrs and a specific galectin inhibitor at the time of original seeding. There was a
statistically significant difference across galectin inhibitor treatment groups when
measuring H2O2 production (F6,1 = 82.039, p < 0.001). Although, treatment with lactose (p
< 0.05), and lactobionic acid (p < 0.001) showed a significant increase in H2O2 production
indicative of increased cellular differentiation; treatment with OTX008 significantly
decreased (p < 0.001) H2O2 production indicative of decreased cellular differentiation
(Figure 12).

54

A

B

C

D

E

F

55

Figure 11. Galectin-specific and non-specific inhibitory sugars increased HL-60 cell
doubling time.
Cell proliferation of HL-60 cells represented as the doubling time over 5 days treated with
non-specific sugars such as (A) α-MM and (B) mannose and specific galectin inhibitors
including (C) lactose, (D) lactobionic acid, (E) TDG and (F) OTX008. The data represent
the mean ± SE n = 4-5. Significant differences among treatments were determined using
ANOVA followed by a Tukey’s HSD test considering *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 12. Galectin-specific and non-specific inhibitory sugars differentially affected
DMSO-induced HL-60 neutrophilic differentiation.
Rate of H2O2 production (pmol/sec/1E6 cells, standardized to fold expression), as a
measure of cellular differentiation induced by the chemotactic peptide 100 nM fMLP by
HL-60 cells 72 hrs post treatment with 1.3% DMSO alone and in combination with various
galectin inhibitors. The data represent the mean ± SD, n = 5-9. Significant differences
among treatments were determined using ANOVA followed by a Tukey’s HSD test
considering *p < 0.05, **p < 0.01, ***p < 0.001.
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3.4 Modification of the redox environment impacted DMSOinduced neutrophilic differentiation.
In light of the observation that the antioxidant NAC impacted galectin expression during
neutrophilic differentiation; I sought to test the effect of both oxidative stress inducer
menadione and NAC on HL-60 neutrophilic differentiation as measured by fMLP induced
H2O2 production (Figure 13A, B). There was a statistically significant reduction in DMSOinduced differentiation following NAC treatment (Figure 13A) (F3,1 = 41.54, p < 0.001),
(Figure 13B) (F5,1 = 125.73, p < 0.001) as determined by one-way ANOVA. DMSO (1.3%)
administered in conjunction with 2.5 mM NAC for 72 hrs showed a significant decrease (p
< 0.001) in H2O2 production rates in comparison to the positive control indicating that
quenching ROS during differentiation was able to diminish levels of the neutrophilic
phenotype (Figure 13A). Interestingly, adding 0.65% DMSO in conjunction with 10 μM
menadione did not significantly increase levels of H2O2 compared to 0.65% alone (Figure
13B). However, the antioxidant NAC was still capable of significantly decreasing levels of
H2O2 produced by 0.65% DMSO alone (p < 0.05), and in conjunction with 10 μM
menadione (p < 0.01) (Figure 13B). Complete attenuation of H2O2 production similar to
untreated levels was not observed, indicating a small synergistic effect of 0.65% DMSO
with 10 μM menadione (Figure 13B).

3.5 DNA methylation regulated galectin transcript and
protein levels in HL-60 cells.
DNA demethylation has been reported to induce cellular differentiation of HL-60 cells
(Schwartsmann et al., 1987); therefore, I sought to investigate the effect of DNA
methylation on galectin gene expression by using decitabine – an inhibitor of DNA
methyltransferases. HL-60 RNA was isolated for RT-qPCR following treatment with 50
nM decitabine and/or 0.65 – 1.3% DMSO for 72 hrs to determine relative p47phox
transcript levels (Figure 14B). Treatment with 50 nM decitabine showed a significant
increase (p < 0.05) in p47phox expression indicating the potential for this drug to increase
HL-60 cell differentiation (Figure 14A). Interestingly, co-treatment with 0.65% DMSO
and 50 nM decitabine displayed a synergistic effect on p47phox induction in comparison
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Figure 13. Modification of the redox environment changes the HL-60 final
differentiated phenotype.
Rate of H2O2 production as a measure of cellular differentiation induced by the chemotactic
peptide 100 nM fMLP by HL-60 cells 72 hrs post treatment with 0.65 – 1.3% DMSO alone
and in combination with 10 μM menadione or 2.5 mM NAC, or both. Panels (A) and (B)
represent individual experiments under different treatments. Significant differences among
treatments were determined using ANOVA followed by a Tukey’s HSD test and are
represented as different letters, considering p < 0.05. The data represent the mean ± SD, n
= 3-5.
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Figure 14. Inhibition of DNA methyltransferases upregulated the differentiation
marker, p47phox.
∆∆Ct relative p47phox transcript levels in HL-60 cells treated with (A) 50 nM decitabine
for 72 hrs or (B) 0.65 – 1.3% DMSO with or without 50 nM decitabine relative to untreated
cells, using RT-qPCR. GAPDH was used as an internal control. The data represent the
mean ± SD, panel (A) n = 3, (B) n = 1. Significant differences among treatments were
determined using ANOVA followed by a Tukey’s HSD test considering *p < 0.05, **p <
0.01, ***p < 0.001.
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Figure 15. Inhibition of DNA methyltransferases induced changes in galectin
transcript and protein levels.
(A) ∆∆Ct relative galectin transcript expression in HL-60 cells treated with 50 nM
decitabine relative to untreated cells, using RT-qPCR. The data represent the mean ± SD,
n = 3-4. Significant differences between treatments were determined using an independent
samples T-test considering *p < 0.05, **p < 0.01, ***p < 0.001. GAPDH was used as an
internal control. (B) Immunoblots for galectin protein expression in HL-60 cells treated
with 50 nM decitabine for 72 hrs. β-actin was used as a loading control. The data represent
the mean ± SD, n = 3. (C) Quantification of galectin levels by densitometric analysis.
Significant differences among treatments were determined using ANOVA followed by a
Tukey’s HSD test considering *p < 0.05, **p < 0.01, ***p < 0.001.
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to treatment with either 0.65% DMSO or 50 nM decitabine, alone (Figure 14B). Therefore,
decitabine works synergistically with DMSO to induce the differentiated phenotype.
The HL-60 galectin expression profile was determined following treatment with 50 nM
decitabine at both the transcript and protein level (Figure 15). There was a statistically
significant difference between galectins (F5,1 = 67.14, p < 0.001) following treatment with
50 nM decitabine as determined by one-way ANOVA. Treatment with decitabine
significantly increased LGALS1, LGALS3, LGALS10 and LGALS12 transcript levels (p <
0.001, p < 0.05, p < 0.05 and p < 0.01, respectively) (Figure 15A). Additionally, a
significant decrease in expression (p < 0.05) was observed with LGALS9 (Figure 15A).
There was a statistically significant change across galectin protein expression levels (F3,1 =
33.56, p < 0.001) following treatment with 50 nM decitabine as determined by one-way
ANOVA. Western blots showed a significant increase of galectin-1, -3, and -10 expression
(p < 0.05, p < 0.001 and p < 0.01, respectively) (Figure 15B, C). Interestingly, an increase
in galectin-12 expression was not observed at the protein level (Figure 15B, C).

3.6 The JNK signaling pathway was differentially regulated
in response to oxidative stress and HL-60 neutrophilic
differentiation and regulates galectin transcript levels.
The effect of JNK signaling on galectin transcript levels was investigated using the JNK
inhibitor SP600125 (Figure 16A), and activator anisomycin (Figure 16B) followed by RTqPCR analysis. Significant differences in galectin transcript levels were determined
following treatment with SP600125 (F5,1 = 22.579, p < 0.001), and anisomycin (F5,1 =
112.39, p < 0.001) as indicated by one-way ANOVA. Interestingly, inhibition of JNK
signaling increased LGALS1 and LGALS12 transcript levels (p < 0.01 and p < 0.05,
respectively), and significantly decreased LGALS8, LGALS9 and LGALS10 levels (p <
0.01, p < 0.001 and p < 0.001, respectively) (Figure 16A). Activation of JNK signaling
increased expression of LGALS1, LGALS3 and LGALS8 (p < 0.05, p < 0.01 and p < 0.01,
respectively) while significantly decreased LGALS9 and LGALS12 expression (p < 0.05
and p < 0.05, respectively) (Figure 16B). These data indicate that galectins are
differentially regulated by the JNK signaling pathway and that other signaling pathways
(i.e. MAPKs) may also regulate galectin expression as a compensatory response.
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Figure 16. JNK signaling altered galectin levels and was differentially regulated
during oxidative stress and DMSO-induced neutrophilic differentiation.
∆∆Ct relative galectin transcript levels in HL-60 cells treated with either JNK inhibitor (A)
25 μM SP600125 or activator (B) 400 nM anisomycin, respectively for 24 hrs, relative to
untreated cells using RT-qPCR. The data represent the mean ± SD, n = 3. Significant
differences between treatments were determined using an independent samples T-test
considering *p < 0.05, **p < 0.01, ***p < 0.001. Immunoblots for phosphorylated JNK
and total JNK levels in HL-60 cells treated with (C) 10 μM menadione with or without 1
mM NAC for 24 hrs (D) 1.3% DMSO with or without 2.5 mM NAC for 72 hrs, n = 3.
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To determine endogenous phosphorylated JNK levels during oxidative stress and DMSOinduced neutrophilic differentiation, western blotting for phosphorylated JNK and total
JNK was performed. Oxidative stress increased phosphorylated JNK levels, which were
attenuated with NAC (Figure 16C). In contrast, differentiation of HL-60 was accompanied
by decreased phosphorylated JNK levels (Figure 16C).

3.7 Correlative analysis between galectins, oxidative stress
and cellular differentiation suggest galectins as
biomarkers of cellular stress responses.
To identify a specific correlation between galectins, oxidative stress and cellular
differentiation a Pearson’s correlation was computed based on treatments with 1.3%
DMSO, 10 µM menadione, 50 nM decitabine, 25 µM SP600125 and 400 nM anisomycin.
This test measures the strength of linear association between two genes. ho-1 was used as
a marker of menadione-induced oxidative stress while p47phox was used as marker of
cellular differentiation. The Pearson’s correlation test revealed a significant positive
correlation in the expression of oxidative stress marker ho-1 with LGALS1 (p < 0.05, R2 =
0.400, n = 15), LGALS3 (p < 0.001, R2 = 0.756, n = 15), and LGALS8 (p < 0.01, R2 = 0.570,
n = 15) while a significant negative correlation was observed with LGALS12 (p < 0.01, R2
= 0.426, n = 15) (Figure 17A, B, C, F).
Correlations were also determined between transcript levels of the cellular differentiation
marker p47phox and galectins (Figure 18). In particular, there was a significant positive
correlation of expression of p47phox with LGALS3 (p < 0.001, R2 = 0.723, n = 12), LGALS9
(p < 0.05, R2 = 0.424, n = 12), and LGALS10 (p < 0.001, R2 = 0.868, n = 12) while a
significant negative correlation was observed with LGALS1 (p < 0.001, R2 = 0.691, n =
12), and LGALS12 (p < 0.05, R2 = 0.456, n = 12) (Figure 18A, B, D, E, F).
Correlations between transcript levels of individual galectins were also tested to determine
expression patterns and the possibility for expression redundancy, across all treatments
(Figure 19). Pearson’s correlation analyses identified a significant correlation between
LGALS1 with LGALS3 (p < 0.05, R2 = 0.302, n = 15), LGALS8 (p < 0.01, R2 = 0.547, n =
15), and LGALS12 (p < 0.01, R2 = 0.641, n = 12) while a significant negative correlation
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Figure 17. Correlation in transcript levels between galectins and the oxidative stress
marker ho-1.
∆∆Ct relative galectin and ho-1 transcript levels in HL-60 cells treated with (●) 1.3%
DMSO, (■) 10 µM menadione, (▲) 50 nM decitabine, (▼) 25 µM SP600125 and (◆) 400
nM anisomycin, (A) LGALS1, (B) LGALS3, (C) LGALS8, (D) LGALS9, (E) LGALS10 and
(F) LGALS12. GAPDH was used as an internal control. Significant correlation between
genes was determined using the Pearson’s correlation test considering p < 0.05, n = 3 for
each treatment.
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Figure 18. Correlation in transcript levels between galectins and marker of HL-60
cell neutrophilic differentiation p47phox.
∆∆Ct relative galectin and p47phox transcript levels in HL-60 cells treated with (●) 1.3%
DMSO, (■) 10 µM menadione, (▲) 50 nM decitabine, (▼) 25 µM SP600125 and (◆) 400
nM anisomycin. (A) LGALS1, (B) LGALS3, (C) LGALS8, (D) LGALS9, (E) LGALS10 and
(F) LGALS12. GAPDH was used as an internal control. Significant correlation between
genes was determined using the Pearson’s correlation test considering p < 0.05, n = 3 for
each treatment.
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Figure 19. Correlation between galectin transcript levels.
∆∆Ct relative galectin transcript levels in HL-60 cells treated with (●) 1.3% DMSO, (■)
10 µM menadione, (▲) 50 nM decitabine, (▼) 25 µM SP600125 and (◆) 400 nM
anisomycin. Correlations were made between each individual galectin vs.: (A–D) LGALS1,
(E–G) LGALS3, (H–I) LGALS8, (J) LGALS9 and (K) LGALS12. GAPDH was used as an
internal control. Significant correlation between gene expressions was determined using
the Pearson’s correlation test considering p < 0.05, n = 3 for each treatment.
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Figure 20. Correlation between oxidative stress and cellular differentiation.
∆∆Ct relative ho-1 and p47phox transcript levels in HL-60 cells treated with (●) 1.3%
DMSO, (■) 10 µM menadione, (▲) 50 nM decitabine and (▼) 25 µM SP600125. GAPDH
was used as an internal control. Significant correlation between genes was determined
using the Pearson’s correlation test considering p < 0.05, n = 3 for each treatment.
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was observed with LGALS9 (p < 0.01, R2 = 0.422, n = 15) (Figure 19A, B, C, D). When
correlating galectin transcript levels with LGALS3, there was a significant positive
correlation with LGALS8 (p < 0.001, R2 = 0.659, n = 15), and LGALS9 (p < 0.05, R2 =
0.390, n = 12) while a significant negative correlation was observed with LGALS12 (p <
0.001, R2 = 0.851, n = 12) (Figure 19E, F, G). Further, the Pearson’s correlation analyses
identified a significant negative correlation between LGALS8 with LGALS9 levels (p <
0.05, R2 = 0.382, n = 15), and LGALS12 (p < 0.05, R2 = 0.328, n = 15) (Figure 19H, I). This
test also revealed a significant positive correlation between LGALS9 with LGALS10
expression (p < 0.05, R2 = 0.405, n = 12) (Figure 19J). Finally, the Pearson’s correlation
analyses identified a significant positive correlation between LGALS10 and LGALS12
expression (p < 0.001, R2 = 0.693, n = 15) (Figure 19K).
Lastly, to identify a link between oxidative stress and cellular differentiation, a Pearson’s
correlation test was computed to determine their relationship (Figure 20). This test
identified a significant positive correlation between oxidative stress marker, ho-1 and the
cellular differentiation marker, p47phox (p < 0.001, R2 = 0.882, n = 12) (Figure 20).
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Chapter 4

4

Discussion

The findings of my study demonstrate that oxidative stress sensitive galectins are involved
with HL-60 neutrophilic differentiation. The first objective utilized immunoblotting and
RT-qPCR techniques to define galectin-1, -3 and -10 as key stress-sensitive galectins that
are similarly regulated under oxidative stress and neutrophilic differentiation. Additionally,
the other galectins indicate minor similarities and differences between expression profiles
of HL-60 including differential regulation of galectin-9 and -12. Competitive galectin
inhibition with inhibitory sugar TDG and the selective small-molecule inhibitor OTX008
were used to investigate the second objective and demonstrate the relevance of galectins in
promoting cellular proliferation. Similarly, both galectin-specific and non-specific
inhibitory sugars differentially effected H2O2 production by HL-60 cells indicating
galectins are involved with both the promotion and potential inhibition of DMSO-induced
neutrophilic differentiation. Investigation of the third objective with immunoblotting and
RT-qPCR techniques revealed the direct effect of DNA hypomethylation and JNK
signaling on upregulating galectin transcript levels. Inhibition of DNA methyltransferases
increased the same stress-sensitive galectins (LGALS1, LGALS3, and LGALS10) regulated
during oxidative stress and differentiation. Immunoblotting for JNK levels indicate that
this pathway is differentially regulated under oxidative stress and neutrophilic
differentiation despite these two processes inducing similar galectin expression profiles.

4.1 Interpretation
4.1.1

Oxidative stress and neutrophilic differentiation induce similar
galectin expression profiles.

There is a precedent for increased galectin expression during oxidative stress. Specifically,
galectin-1 and -3 have been shown to display a protective role against the harmful effects
of increased ROS production (Ito et al., 2011; Martínez-Martínez et al., 2014). However,
the role of increased galectin expression following oxidative stress may also be related to
these proteins being involved with apoptotic pathways. Galectin-3, for example, has been
reported to both induce (Xue et al., 2013), and inhibit (Hoyer et al., 2004) apoptosis in
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lymphocytic cell lineages. However, Matarrese et al. (2000) showed that overexpression
of galectin-3 in breast cancer cells provides a protective effect from menadione-induced
ROS, suggesting antioxidant-like properties of galectin-3 (Matarrese et al., 2000). The
decreased expression of LGALS9 is probably related to its often down-regulated expression
within tumour cells (which undergo cellular stress including oxidative stress) in
comparison to normal cells (Heusschen et al., 2013). However, signals related to
inflammatory responses such as LPS have been reported to elevate galectin-9 mRNA
levels, indicating stress-specific expression of this galectin (Kasamatsu et al., 2005).
Increased expression of LGALS1, LGALS3 and LGALS10 during oxidative stress indicate
a common regulatory method amongst these galectins (Figure 5). In particular, Sp1 has
been suggested to regulate transcription of these galectins considering the many possible
Sp1 transcriptional binding spots amongst their promoters (Dyer and Rosenberg, 2001).
Additionally, Sp1 has been identified as a redox-sensitive transcription factor (Chu and
Ferro, 2006). Specifically, activation of the PP1-JNK-Sp1 signaling pathway via ROS
promotes the phosphorylation and subsequent activation (and translocation to the nucleus)
of transcription factor Sp1 (Chu and Ferro, 2006). Although LGALS9 was generally
downregulated in my study (Figure 5 and Figure 9); this galectin has been reported being
involved with many of the same stress sensitive pathways that increase galectin transcript
levels indicating galectin regulatory mechanism overlap (Laderach et al., 2010). The stable
expression of LGALS8 is interesting considering its vast differential expression across
many different normal and tumour lines (Elola et al., 2014; Lahm et al., 2001).
Unfortunately, little is known about LGALS8 regarding the transcriptional and translational
machinery with respect to stress-sensitive models (Timoshenko, 2015). Similarly, despite
evidence suggesting involvement of LGALS12 redox-sensitive pathways (Yang et al.,
2004), little is known about this galectin with respect to regulatory methods involved with
cell stress. Although this galectin is reported to play a role within adipose tissue
development, its expression is influenced among insulin-signaling, oxidative stress and
inflammatory-related signaling pathways (Li et al., 2010).
The expression changes associated with DMSO-induced neutrophilic differentiation of
HL-60 cells are interesting for two reasons. First, the expression pattern observed during
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differentiation was markedly stronger than that of oxidative stress (Figure 9). And second,
generally, the expression pattern – in regards to down- and up-regulation of galectins – was
similar to that of oxidative stress. Specifically, there is an upregulation with LGALS3 and
LGALS10 that was also observed at the protein level with galectin-1. This indicates the
potential for an association between oxidative stress and neutrophilic differentiation based
on galectin expression patterning. Partial attenuation of LGALS3 and LGALS10 expression
following NAC administration with DMSO-induced differentiation is in accordance with
another study showing NAC supplementation reduces differentiation marker expression
during HL-60 differentiation (Krance et al., 2010). Complete attenuation was not achieved
suggesting that other molecular mechanisms are at play for galectin expression. For
example, both galectin-1 and galectin-3 are involved with regulating apoptosis in T-cells
(Stillman et al., 2006), a process that is commonly associated with the development of
immune cells (Opferman, 2008). The similar expression pattern observed between
galectin-1, -3 and -10 can be expected considering the high level of amino acid sequence
homology specifically between these galectins (Leonidas et al., 1995). Non-varying
expression of LGALS8 during cellular differentiation is expected considering its expression
has been shown to be stable during eosinophil-, monocyte- and neutrophil-like
differentiation of HL-60 cells (Abedin et al., 2003). The following expression profiles
indicate the potential for galectins as targets in disease diagnosis, prognosis and clinical
therapeutic models. Unfortunately, therapeutic strategies associated with acute myeloid
leukemia (AML) have reached their limit of effectiveness (Zhou et al., 2013). Considering
the strong association between ROS and hematopoietic stem cell differentiation, galectins
may represent ideal candidates for targeted treatment against AML.

4.1.2

Galectin-specific and non-specific inhibitory sugars and
modification of the redox environment using NAC decreased
cellular proliferation and impacted the HL-60 cell differentiated
phenotype.

The use of galectin inhibitors on HL-60 cell proliferation showed varied results. Although
all sugars showed a trend toward decreased cell proliferation in a dose-dependent manner;
only TDG and OTX008 significantly increased the cell doubling time (Figure 11E, F). Both
of these inhibitors are known to inhibit galectin-1 suggesting this galectins involvement
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with cellular proliferation. Galectin-1 has been show to demonstrate conflicting roles
during cell proliferation depending on its localization and cell type. In particular,
extracellular galectin-1 has been reported to bind α5β1 integrin in order to inhibit cellular
proliferation through increased Sp1 transactivation in carcinoma cell lines (Fischer et al.,
2005), while intracellular galectin-1 can enhance cell proliferation through protein-protein
interactions with RAS (Prior et al., 2003). The effect on cell proliferation observed with
the galectin-1 inhibitor OTX008, has also been reported to inhibit endothelial cell
proliferation (Dings et al., 2006). OTX008 is unable to affect galectin-1s interaction with
ECM components but rather its proposed mechanism of action is through regulating
galectin-1 interaction with intracellular components involved with cell cycle components
directly (Astorgues-Xerri et al., 2014). Since lactose exhibited no inhibitory effect despite
its reported relatively low dissociation constant value (Kd) with galectin-1 at 12.4 µM in
HL-60 cells and 64 µM in bovine tissue and with galectin-3 at 55.2 µM (Schwarz et al.,
1998; Stowell et al., 2008), these galectins then may mediate cellular proliferation through
CRD-independent interactions. Interestingly, Cedeno-Laurent et al. (2012) demonstrate
that lactose attenuates the modulatory effect of galectin-1 on cell proliferation in T-cells
further indicating that the effect of galectin-1 on cell proliferation is cell type dependent
(Cedeno-Laurent et al., 2012). TDG demonstrated an inhibitory effect on HL-60 cellular
proliferation (Figure 11E). TDGs effect on HL-60 cell proliferation can be attributed to –
unlike lactose – its stronger binding affinity to galectin-1 and -3 with Kd values of 24 µM
and 43 µM, respectively, and increased metabolic stability (van Hattum et al., 2013).
Maeda et al. (2003) report similar results whereby galectin-1 and -3 stimulate hepatic cell
proliferation through activation of the ERK pathway and this effect was attenuated by TDG
(Maeda et al., 2003). α-MM and mannose were used to assess their potential inhibition of
galectin-10 during cellular proliferation. My results indicate that despite galectin-10s
preferential binding for mannosyl residues over galactosyl residues, galectin-10 does not
contribute to cellular proliferation of HL-60 in a CRD-dependent way (Figure 11A, B).
Galectin-8 maintains a lower binding avidity (Kd = 130 µM–150 µM) toward lactose
compared to the other galectins (Hirabayashi et al., 2002; Ideo et al., 2003). Interestingly,
Cattaneo et al. (2011) provide evidence that both lactose and TDG inhibited galectin-8 in
peripheral blood mononuclear cells (PBMCs) at concentrations of 50 mM and 30 mM,
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respectively (Cattaneo et al., 2011). Similarly, 50 mM lactose was used to inhibit
recombinant galectin-3 stimulated cell proliferation in fibroblasts (Inohara et al., 1998),
and preadipocytes (Kiwaki et al., 2007). Thus, HL-60 cell proliferation may not be
inhibited by lactose at my experimental concentrations despite relatively low dissociation
constants whereas TDG falls within my tested range (Figure 11C, E).
OTX008 was able to decrease fMLP induced H2O2 production indicating that the
expression of galectin-1 is important for the process of differentiation (Figure 12).
Galectin-1 expression has been reported to play a role in the differentiation of dendritic
cells (Fulcher et al., 2009), thymocytes (Liu et al., 2008b), and both B- and T- cells (Espeli
et al., 2009; Liu et al., 2009). Interestingly, TDG did not have an effect on neutrophilic
differentiation despite its ability to inhibit galectins, which mediate cellular proliferation.
Thus, the expression of other galectins including -3, -10 and -12 may be associated with
the direct effect of differentiation including apoptosis, cycle arrest and the indirect effect
of cytotoxicity induced by DMSO. Interestingly, ~30% of cells are apoptotic following
cellular differentiation through the activation of caspases and MAPK pathways (Duval et
al., 2006). My findings indicate no change in differentiation following the addition of TDG
after DMSO-induced differentiation (Figure 12) despite an inhibitory effect of this drug on
T-cell differentiation (de la Fuente et al., 2014). T-cell differentiation is reported to be
dependent on galectin-1 binding to CD69 (de la Fuente et al., 2014). Considering OTX008
inhibited differentiation while TDG did not, HL-60 neutrophilic differentiation may be, in
part, mediated through CRD-independent function of galectin-1. Surprisingly, lactose and
lactobionic acid treatment induced increased levels of ROS production indicating
“enhanced” neutrophilic differentiation and the potential for galectins to have an inhibitory
effect on differentiation (Figure 12). One similar example includes galectin-3s ability to
inhibit osteoblast differentiation, which was attenuated via the addition of lactose
(Nakajima et al., 2014). Additionally, galectin-12 is downregulated following neutrophilic
differentiation of promyelocytes indicating that lactose and lactobionic acid may be
inhibiting galectin-12 expression and subsequently increasing differentiation (Xue et al.,
2016). The extent of which some inhibitors work while others do not remains elusive;
however, differences between the binding affinities for these inhibitors toward all galectins
may provide an explanation for the varying effect on differentiation. Additionally,
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determining the glycoreceptor content/profile/structure on the cell surface of HL-60 would
provide more details as to which glycans represent a significant binding partner to certain
galectins over others.
To better understand the role of oxidative stress and its potential association with
neutrophilic differentiation, modification of the redox environment using menadione and
NAC during differentiation was investigated. My results indicate that menadione, a redox
cycling compound was unable to “enhance” neutrophilic differentiation. Ogino et al.
(2010) reported an enhanced effect during differentiation when using the direct oxidant:
H2O2 (Ogino et al., 2010). Typically, reductive enzymes including NADPH-ubiquinone
oxidoreductase and NADPH-cytochrome P450 metabolize menadione by one electron
reduction, which subsequently undergoes redox cycling in the presence of oxygen to
produce superoxide anion. However, other reductive enzymes including NADPH quinone
oxidoreductase 1 (NQO1) metabolize menadione via a 2 electron reduction step, which
creates a stable hydroquinone that is unable to enter redox cycling and generate ROS.
NQO1 is thought to be a cellular detoxifying mechanism (Criddle et al., 2006), and
therefore the oxidative stress induced by menadione may be quickly reversed via increased
NQO1 expression. Criddle et al. (2007) reported the effect of menadione is highly
dependent on NQO1 expression (Criddle et al., 2007). Further, increased NQO1 expression
is observed during cellular differentiation alone indicating the abundance of this enzyme
present during this process and therefore negating the effect of any quinones present (Zhao
et al., 2009).
Administration of NAC decreased DMSO-induced neutrophilic differentiation as
measured by fMLP induced ROS production (Figure 13A, B). Further, NAC is able to
inhibit both adipocyte differentiation of mouse embryonic fibroblasts and macrophagic
differentiation of HL-60, via downregulation of ERK and JNK phosphorylation (Chien et
al., 2013; Pieralisi et al., 2016). Similarly, inhibition of ROS production decreases
monocytic differentiation into macrophages through the ERK pathway (Zhang et al., 2013).
Interestingly, Chen et al. (2012) report that ROS produced from NADPH oxidase during
HL-60 cell differentiation are essential for this process (Chen et al., 2012). Moreover,
inhibition with antioxidants is able to inhibit the final differentiated phenotype, while the
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opposite is also true. Specifically, the differentiation of promyelocytic leukemia cells
(NB4) is enhanced when superoxide dismutase is inhibited with siRNA while
differentiation is inhibited through endogenous ROS quenching with antioxidant, NAC
(Yang et al. 2015). Perhaps then, only endogenous levels of ROS production are required
for differentiation and exogenous chemical inducers of ROS are redundant. This may
explain menadiones inability to significantly increase levels of differentiation alone (Figure
13A).

4.1.3

Inhibition of DNA methyltransferases induced a similar
galectin expression pattern to that produced by oxidative
stress and neutrophilic differentiation.

DNA methylation was investigated as a regulatory mechanism of galectin expression
considering inhibition of DNA methyltransferases is associated with increased
differentiation in leukemic cell lines (Qin et al., 2007). My results indicate increased
differentiation following DNA hypomethylation with decitabine considering the marked
significant increase in differentiation marker, p47phox (Figure 14A, B). Interestingly, the
expression profile of HL-60 cells in response to decitabine (Figure 15) is similar to
expression profiles induced by oxidative stress and neutrophilic cellular differentiation.
Specifically, treatment with decitabine increased expression of galectin-1, -3 and -10 at
both the transcript and protein levels (Figure 15). This suggests that promoter
demethylation is, in part, responsible for regulating LGALS1, LGALS3 and LGALS10 levels
during the oxidative stress response and HL-60 cell differentiation. Epigenetic changes
including promoter hypermethylation are early events in neoplastic processes and
contribute by silencing tumour suppressor genes (Jones and Baylin, 2002). In fact,
methylated genes have been evaluated as biomarkers for detection of cancer (Fackler et al.,
2004). In particular, hypermethylation of the LGALS3 promoter has been validated as a
marker for early diagnosis of prostate (Ahmed et al., 2009), and thyroid cancers (Keller et
al., 2013). Similarly, the LGALS1 promoter is hypermethylated in colorectal
adenocarcinoma cells and re-expression of this gene induces apoptosis (Satelli and Rao,
2011). My study provides the first evidence of LGALS10 promoter methylation and its
marked expression change over other galectins following decitabine treatment (Figure
15A). Additionally, my study provides evidence for galectin-10 as a marker for oxidative
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stress and cellular differentiation in the context of AML. Although no DNA methylation
regulatory mechanism has been reported to transcriptionally regulate LGALS10, the
promoter region shares many sequence similarities to that of LGALS1 and LGALS3,
specifically, Sp1 binding sites (Dyer and Rosenberg, 2001). Interestingly, the transcription
factor Sp1 has been reported to bind promoter regions sensitive to methylation and
therefore protect genes from transcription repression (Höller et al., 1988). The decrease in
LGALS9 gene expression following DNA demethylation (Figure 15A) indicates the
potential for this galectin to be regulated by transcription factors that are repressed via
methylation. Most interesting, the increase in LGALS12 expression following treatment
with decitabine (Figure 15A) is not associated with the decrease observed following
neutrophilic differentiation. Xue et al. (2016) report an inhibitory function for galectin-12
during neutrophilic differentiation suggesting multiple and complex regulatory
mechanisms for this galectin (Xue et al., 2016).

4.1.4

JNK signaling is impacted by oxidative stress
differentiation and induces galectin expression.

and

Perhaps most interesting is the contrasting regulatory effect of JNK signaling observed
during oxidative stress and neutrophilic differentiation. Increased phosphorylated JNK
levels were observed during oxidative stress while the opposite effect was seen during
differentiation (Figure 16C, D). Further, the addition of NAC with menadione was able to
rescue basal protein levels while the addition of NAC with DMSO had no effect (Figure
16D). This indicates that JNK signaling during neutrophilic differentiation is not redoxsensitive and that the LGALS3 and LGALS10 expression attenuated with the addition of
NAC (Figure 9) may be done through other redox-sensitive MAPK pathways, i.e. p38 and
ERK signaling. This effect may explain the differences in the galectin expression profiles
of both processes. Differential phosphorylation of JNK in HL-60 cells is most likely
dependent on the stimulus used and the incubation time, following treatment. For example,
Wang and Studzinski (2001) showed that 96 hr DMSO-induced differentiation of HL-60
is accompanied by a decrease in phosphorylated JNK levels while the inhibition of the p38
MAPK pathway increases levels of phosphorylated JNK but only in response to 1,23 D3induced monocytic differentiation (and not neutrophilic). Further, TPA-induced
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differentiation of HL-60 shows only a transient (~1 hr) increase in phosphorylated JNK
before returning to control levels while still showing prominent levels of phosphorylated
ERK (Chien et al., 2013). In fact, most studies show – through the use of JNK inhibitor
SP600125 – that increased signaling through this pathway is not involved in HL-60
differentiation (Chung et al., 2005; Yu et al., 2008). Therefore, it is probable that
differential JNK levels during differentiation is a result of the inhibition or augmentation
of other MAPK pathways. Increased phosphorylated JNK during oxidative stress,
however, has been reported in a number of other studies (Kaneto et al., 2004; Wang et al.,
2008). Interestingly, JNK signaling has been reported as a protective mechanism against
oxidative stress by inducing expression of protective genes (Wang et al., 2003; Wu et al.,
2009). Therefore, this may explain the observed downregulation of JNK signaling
following neutrophilic differentiation – these genes are not necessary considering oxidative
stress is needed in the promotion of differentiation. Additionally, this also helps explain
the associated induction of apoptosis during differentiation. These results provide more
evidence of the importance of JNK signaling during neutrophilic differentiation and insight
into the treatment of AML differentiation through MAPK pathways associated with
galectin expression.
Both an inhibitor (SP600125), and activator (anisomycin) were used to investigate the role
of direct JNK signaling on galectin expression (Figure 16A, B). Inhibition of JNK signaling
led to decreased galectin expression while augmentation of this pathway increased galectin
expression. Increased LGALS1 expression may be a result of an indirect (off/non-target)
effect caused by inhibition of the JNK signaling pathway. For example, inhibition of
specific MAPK pathways can drastically increase the expression of others (Wang and
Studzinski, 2001). Specifically, inhibition of the p38 MAPK pathway potentiated the JNK
pathway leading to activation of transcription factors implicated in HL-60 differentiation
(Wang and Studzinski, 2001). Many MAPK pathways crosstalk with each other and often
affect the same set of target genes. Therefore LGALS1 may be indirectly regulated through
either ERK or p38 signaling as a compensatory response (Shen et al., 2003). A similar
effect of decreased LGALS9 expression has been reported following inhibition of JNK
signaling with SP600125 (Steelman et al., 2013); however, a subsequent decrease
following exposure to anisomycin has not been investigated. Activation of LGALS10 has
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been reported being reliant on AP-1 and Oct1 transcription factors binding to the GC box
(Dyer and Rosenberg, 2001). AP-1 is heavily regulated through MAPK signaling pathways
indicating the reported downregulation of LGALS10 is likely through decreased JNK
signaling (Karin, 1995). The increase in LGALS12 expression following treatment with
SP600125 (Figure 16A) is interesting considering its downregulation following
neutrophilic differentiation, which is accompanied by decreased phosphorylated JNK
levels. Thus, in the context of cellular differentiation LGALS12 is regulated through various
networks besides JNK signaling. These data indicate the potential for off-target effects on
galectin expression following regulation of JNK and the specificity for JNK signaling on
only certain galectins.

4.1.5

Galectin gene expression correlates with oxidative stress and
differentiation.

The correlation analysis indicates that there is both a strong positive and negative
correlation of galectins with oxidative stress. Correlations between galectins with ho-1 and
p47phox are indicative of galectins participating in both oxidative stress responses and
differentiation, respectively. In particular, LGALS1, LGALS3 and LGALS8 were positively
correlated with oxidative stress marker ho-1 (Figure 17A, B, C) whereas LGALS3, LGALS9
and LGALS10 positively correlated with cellular differentiation marker p47phox (Figure
18B, D, E). These findings suggest galectins as biomarkers of oxidative stress in the context
of leukemia. Both LGALS1 and LGALS3 have been proposed as biomarkers of other
cancers such as renal cell carcinoma – a malignant tumour typically associated with levels
of oxidative stress (Ganesamoni et al., 2012; von Klot et al., 2014). More generally,
galectin-3 has been proposed as a marker of fibrosis, which is a process highly associated
with oxidative stress in the context of cardiovascular diseases (Hrynchyshyn et al., 2013).
Additionally, LGALS12 negatively correlated with both ho-1 and p47phox (Figure 17F and
Figure 18F). Decreased LGALS12 transcript levels is suggested as an additional biomarker
of cellular stress responses. Decreased LGALS12 transcript levels during neutrophilic
differentiation may be due to this proteins effect on cell cycling (Yang et al., 2001), as it
has been shown that LGALS12 can inhibit human NB4 promyelocytic leukemia cell
differentiation (Xue et al., 2016). Interestingly, LGALS10 only positively correlated with
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p47phox (Figure 18E) while showing no correlation with ho-1 (Figure 17E) indicating the
expression of this galectin is specific for neutrophilic differentiation and its function is
potentially unrelated to its oxidative stress sensitivity. Additionally, galectin-10 has been
proposed as a potential biomarker for eosinophilic airway inflammation based on its
correlation with sputum eosinophil levels (Chua et al., 2012). My findings suggest that
galectin-10 transcript levels may be a ubiquitous marker for other granulocytes in the
context of differentiation. LGALS8 expression did not correlate with differentiation marker
p47phox (Figure 18C). This is interesting considering LGALS8 overexpression has been
shown to enhance osteoclast differentiation (Vinik et al., 2015), and T-cell differentiation
(Sampson et al., 2016). Potentially, LGALS8 role in differentiation is cell type/context
specific. These findings provide insight to expression patterns of galectins in a leukemic
model under oxidative stress and DMSO-induced differentiation.
In order to further analyze galectin expression patterns; correlations between galectin
isoform expressions were performed to determine potential galectin redundancy.
Generally, galectin-8 expression across treatments remained invariable; however, there
was a significant positive correlation between LGALS1 and LGALS8 indicating the
potential for redundancy between these proteins (Figure 19B). Other studies have shown
functional redundancy between galectin-1 and galectin-8 when promoting plasma cell
differentiation (Tsai et al., 2011), and eliciting T-cell responses (Tribulatti et al., 2012). My
results also indicate a significant positive correlation between LGALS1 and LGALS3
transcript levels (Figure 19A). There is a precedent for correlated expression between
LGALS1 and LGALS3 in cancer lines (Wang et al., 2000), however, the function of these
two proteins is likely related to their cellular localization/distribution rather than their
correlation being functionally redundant (Sanjuán et al., 1997). The significant negative
correlation between LGALS8 and LGALS9 transcript levels (Figure 19H) is interesting
considering these two proteins have been shown to exist as multiple splice variants (Nishi
et al., 2006). These variants contain structural similarities allowing these proteins to be
affected by other molecular factors in similar fashion. For example, isoforms of galectin-8
and galectin-9 containing the longest linker peptide regions are more susceptible to
cleavage (Nishi et al., 2006). The correlation existing between transcript levels of these
two galectins is likely due to structural features as a consequence of alternative splicing.
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Future studies should identify expression patterns of individual splicing transcript variants
to confirm my findings or determine new correlations. Interestingly, there was a correlation
with LGALS10 and LGALS12 transcript levels (Figure 19K) indicating the potential for
similar expression patterns and redundancy. No transcript level correlation between these
galectins has been investigated; therefore, future studies should aim to identify similar
expression patterns across other treatments to identify new correlations considering both
galectins are involved within differentiation.
The positive correlation between ho-1 and p47phox transcript levels (Figure 20) indicates
a strong association between oxidative stress and neutrophilic differentiation considering
many galectins correlate with both markers; galectins may be considered biomarkers and
potentially mediators of these two processes. In particular, the link between oxidative stress
and its contribution in promoting differentiation is, in part, through upregulation of
galectins. Although JNK signaling is differentially affected by differentiation and oxidative
stress; galectin expression remains variable indicating not only are galectins biomarkers
for both processes, but galectins may also feedback to promote the differentiation of
promyelocytes in HL-60 cells.
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Figure 21. Suggested pathway of menadione-induced oxidative stress and DMSOinduced neutrophilic differentiation of HL-60 cells.
The above schematic is the proposed method for galectin contribution in DMSO-induced
HL-60 neutrophilic differentiation (Figure 21). It is speculative that JNK signaling works
to increase Sp1 nuclear translocation and activation to increase galectin expression
responsible in promoting cellular differentiation. Additionally, galectin expression by other
MAPK pathways following DMSO treatment is also speculative. However, my study
indicates that increased galectin gene expression following JNK activation, oxidative
stress, and inhibition of DNA methyltransferases, is prominent. ROS signaling must
precede differentiation considering treatment with NAC was able to successfully inhibit
differentiation in all cases. Future studies should include in-depth individual galectin
analyses to identify specific differences between galectins, helping to eliminate the
assumption of functional redundancy.
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4.2 Conclusions and application
In conclusion, I have determined the galectin expression profile of HL-60 cells under
oxidative stress and during DMSO-induced neutrophilic differentiation. Similarities in
galectin expression including upregulating of galectin-1, -3 and -10 at either the transcript
or protein levels indicates an association between cellular differentiation and the redox
environment with respect to galectins. The differential expression of galectins following
oxidant exposure suggests these proteins may represent markers of the cellular stress
response. It also suggests the potential for galectin-1, -3 and -10 as clinical targets when
developing therapeutic treatment for AML.
Using different galectin inhibitors, galectin-1 is, at least, suggested to play a role in cellular
proliferation and the progression of HL-60 cell differentiation. Considering other galectin
inhibitory sugars (besides TDG) displayed no effect on either process, it is likely that these
galectins either are not significantly involved, or are working in a CRD-independent
fashion intracellularly to facilitate their biological role. Additionally, the upregulation of
galectin-1, -3 and -10 following DMSO-induced expression may be an indirect effect of
differentiation, including: apoptosis or cell cycle arrest. These data suggest the complex
role of galectins in HL-60 cell stress response and differentiation despite their widespread
expression and often structural redundancy.
Investigation of the redox environment was accomplished using the oxidant menadione
and antioxidant NAC. My results suggest the addition of NAC is sufficient to reduce the
levels of DMSO-induced neutrophilic differentiation of HL-60 cells while menadione was
unable to enhance this effect. Understanding the role of ROS during differentiation is
important considering the crucial roles of free radicals in the pathogenesis of many diseases
(e.g. cancer due to loss of differentiation) (Ye et al., 2015). Further, considering galectins
are involved with many types of cellular differentiation, the regulatory mechanisms
associating ROS and cellular differentiation may be, in part, mediated through galectin
expression. For example, ROS production has been known to facilitate adipocyte
differentiation, which also requires galectin-12 expression (Lee et al., 2009; Yang et al.,
2004). These results suggest an association between oxidative stress and cellular
differentiation with respect to both up and down regulation of galectins. Finally, these data
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suggest galectins may act as major players in the pathogenesis of diseases attributed to
ROS production.
JNK signaling and DNA methylation are two distinct regulatory methods of galectin
expression during oxidative stress and differentiation. The galectin expression profile
generated from demethylation shows similarities to that of oxidative stress and DMSOinduced neutrophilic differentiation including upregulation of galectins-1, -3 and -10.
Therefore, it is possible that other epigenetic mechanisms are involved with these two
processes with respect to galectin expression. Interestingly, neutrophilic differentiation and
oxidative stress produced distinctly opposite expression patterns with decreased
phosphorylated JNK levels following differentiation and increased levels following the
addition of menadione. This suggests the potential for different MAPK pathways or other
regulatory mechanisms to be involved with galectin expression during these two processes
despite the similarities in expression.
The correlation analysis revealed coordinated galectin expression as a potential biomarker
for oxidative stress and differentiation of HL-60 cells. Specifically, LGALS1, LGALS3 and
LGALS8 may be considered biomarkers of oxidative stress while LGALS3, LGALS9 and
LGALS10 may be considered biomarkers for HL-60 neutrophilic differentiation.
Downregulation of LGALS12 may be considered a negatively correlated biomarker for both
oxidative stress and neutrophilic differentiation. Correlation between marker genes of each
process suggests that galectins act as mediators responsible in promoting differentiation
following oxidative stress. Finally, correlated expression amongst different galectin
indicate the potential for functional redundancy; however, further analysis of individual
galectins is required to draw specific and definite conclusions.
In conclusion, this study demonstrates an association between oxidative stress and
neutrophilic differentiation of HL-60 cells with respect to upregulation of galectins.
Distinct similarities and differences in galectin expression profiles provide insight to
different regulatory mechanisms associated with these processes and the potential for
galectin expression as biomarkers of different biological processes and stress responses. In
particular, galectins and their expression associated with AML and differentiation may be
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considered a clinical target when developing various drug treatments/therapeutic
medication.

4.3 Study limitations and future directions
One major project limitation was the inability for genetic manipulation: specifically
knockdown experiments utilizing RNAi based techniques. Like many leukemic cell lines,
HL-60 cells have been reported as being transfection-incompetent in comparison to other
lines such as K562 (Esendagli et al., 2009). Despite this, more sophisticated methods of
gene delivery such as lentiviral techniques have proven useful for RNAi in the context of
studying HL-60 cellular differentiation (Jian et al., 2011). More recent techniques
including the powerful gene editing tool CRISPR/Cas9 system has proven useful for
manipulating gene expression for studying myeloid leukemia in the context of
differentiation (Valletta et al., 2015). Specifically, CRISPR/Cas9 directed gene knockdown
is very specific and eliminates indirect/off-target effects that may be associated with the
galectin inhibitors used in this study. In this way, I could study the effect inhibiting
galectins that are typically upregulated during differentiation and then test for the
neutrophilic phenotype.
Another method to examine the effect of individual galectins on cellular proliferation other
than genetic manipulation using RNAi would be to utilize glycan modification enzymes/
drugs to alter glycan structure, i.e. remove terminal sialic acid glycan residues. Different
galectins, for example, have shown similar specificity toward LacNac binding; however,
the addition/removal of 2–3-sialic acid on terminal LacNac structures can significantly
change specificity of only specific galectins (Stowell et al., 2008). This method allows for
analyses of only endogenously expressed galectins. Exogenously added recombinant
galectins are often used to assess the role of individual galectins on cellular functions when
added in abundance.
Another study limitation is the use of DMSO as a “specific” inducer of neutrophilic
differentiation. DMSO was originally described to induce neutrophilic differentiation
based on morphological changes (Collins et al., 1979). It has been reported that HL-60
cells induced with DMSO can undergo defective neutrophil maturation evident by failure
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of secondary granule gene expression; therefore, these cells may only represent an atypical
phenotype of proper granulocytes (Khanna-Gupta et al., 1994). In fact, DMSO-induced
differentiation increases CD14 expression: a common marker of monocytic differentiation
into mature macrophages (Zamani et al., 2013). Therefore, future studies should include –
in addition to multiple promyelocytic cell lines – multiple neutrophilic differentiation
stimuli such as all-trans retinoic acid (ATRA) when comparing galectin expression
profiles. This is especially important considering lineage specific differentiation using
various chemical inducers enables different galectin expression profiles (Abedin et al.,
2003). Additionally, investigation of specific transcription factors affected by JNK
signaling should be investigated. In particular, chromatin immunoprecipitation analyses
could be utilized to identify specific interactions between galectin DNA sequences and
relevant transcription factors such as Sp1. Considering expression of specific galectins are
changed during oxidative stress and differentiation, identification of transcription factors
responsible for this increase would offer insight to potentially many signaling pathways.
Another study barrier was the limitation of immortalized cell lines. Animal models would
provide a more physiologically relevant system in order to identify the specific roles of
galectins. The inclusion of primary cultures may also offer a better model for examination
of galectins. Further studies using these more physiological models to confirm the findings
presented here would be the next step to further validate galectins as key regulators of
neutrophilic differentiation and possible regulators of leukemic progression.
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Appendix A: supplementary material

Gene Name
& RefSeq

LGALS1
NM_002305

LGALS3

Sequence, 5’ – 3’

F

Size

2 Step Cycling (RT-qPCR)
3 Step Cycling (RT-PCR)

220bp

Denaturation: 95°C for 5 Sec
Anneal/Extend: 60°C for 25 Sec

CCTGGAGAGTGCCTTCGAGTG

R

CTGCAACACTTCCAGGCTGG

F

CAGAATTGCTTTAGATTTCCAA

LGALS8

R

TTATCCAGCTTTGTATTGCAA

F

TGGGGACGGGAAGAGATCAC

LGALS9

R

TGCCATAAATGCCCAGAGTGTC

F

CTTTCATCACCACCATTCTG

113%

LGALS10

R

ATGTGGAACCTCTGAGCACTG

F

GGATGGCCAAGAATTTGAACTG

R

GGTGTAAGAGGATTGGCCATTG

LGALS12

F

TGTGAGCCTGAGGGACCA

NM_001142
535

p47phox

GCTGAGATCAGTTTCTTCTGC

F

GTCAGATGAAAGCAAAGCGA

ho-1

R

CATAGTTGGGCTCAGGGTCT

F

CTCAAACCTCCAAAAGCC

GAPDH

R

TCAAAAACCACCCCAACCC

F

GAGTCAACGGATTTGGTCGT

R

AATGAAGGGGTCATTGATGG

18202194

112.6%
Denaturation: 95°C for 5 Sec
Anneal/Extend: 62°C for 25 Sec

Designed
Pfaffl

83.6%
Denaturation: 95°C for 5 Sec
Anneal/Extend: 65°C for 25 Sec

18202194
Pfaffl

Denaturation: 95°C for 5 Sec
Anneal/Extend: 60°C for 25 Sec
OR
Extend: 72°C for 60 Sec

Denaturation: 95°C for 30 Sec
Anneal/Extend: 60°C for 30 Sec
OR
Extend: 72°C for 60 Sec

ND*
23147401
∆∆Ct

PMCID: PM
C2175339
-

93.3%
95bp

NM_002046

Denaturation: 95°C for 5 Sec
Anneal/Extend: 62°C for 25 Sec
Pfaffl

220bp

NM_002133

Designed

86.8%

93bp

NM_000265

Denaturation: 95°C for 5 Sec
Anneal/Extend: 62°C for 25 Sec
Pfaffl

111bp
R

18202194

81.4%

82bp

NM_001828

Denaturation: 95°C for 5 Sec
Anneal/Extend: 60°C for 25 Sec
Pfaffl

91bp

NM_009587

23108139
∆∆Ct

172bp

NM_006499

PMCID or
PMID for
reference
(if
applicable)

100%

108bp

NM_002306

PCR
efficiencies &
quantification
method

Denaturation: 95°C for 5 Sec
Anneal/Extend: 62°C for 25 Sec

PMCID: PM
C3489664
Pfaffl
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Table 1. Primer sequences and RedSeq, amplicon size, cycling conditions,
efficiencies, method of quantification and primer references.
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A
slope <- function (data,n){
j.max <- n-1
b1 <- list()
max <- length(data$V1) - n + 1
for (i in 1:max){
d.max <- n+i-1
sub.data <- data[i:d.max,]
b <- list()
m <- 0
for (j in 1:j.max){
k.min <- j+1
for (k in k.min:n){
m <- m + 1
b[m] <- (sub.data[j,2] - sub.data[k,2]) / (sub.data[j,1] - sub.data[k,1])
}
}
b1[i] <- median(unlist(b))
}
b1
x <- which.min(unlist(b1))
r1 <- data[x + round(n/2),1]
r2 <- data[x + round(n/2),2]
r3 <- b1[x]
result <- cbind(r1, r2, r3)
}

B

Algorithm 1. (A) R code used to determine the minimum first derivative of the negative
slope indicative of the time point at which the slope is steepest. Algorithm describes a
moving window of 10 units (seconds) from initial time of reading (0 seconds) to 900
seconds. (B) Example kinetic from fluorometric assay. Illustration shows the moving
window used to determine the steepest point of the slope.
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